Method for donor cell analysis
By detecting the HLA-DR and TIGIT expression levels of donor cells and performing exogenous nucleic acid modification, the problem of donor cell selection and function in CAR T cell therapy was solved, and the in vitro function and therapeutic efficiency of CAR T cells were improved .
Patent Information
- Application Number
- CN202380031483.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-02-24
- Filing Date
- 2023-04-28
- Publication Date
- 2024-11-15
AI Technical Summary
In CAR T cell therapy, autologous CAR T cell preparation has problems such as delayed and functional defects leading to treatment failure, and the supply of allogeneic CAR T cells is complex and costly, and there is a lack of effective methods to identify and select high-quality donor cells.
By detecting the HLA-DR and TIGIT expression levels in donor cells, donor cells with specific biomarker expression profiles are selected and exogenous nucleic acid sequence modifications are performed to reduce or eliminate endogenous gene expression to prepare with improvements Engineered CAR T cells with in vitro function.
Improves the in vitro function of CAR T cells, including improving cytotoxicity and cellular fitness, reducing cytokine secretion, and provides a more homogeneous and efficient therapeutic product.
Smart Images

Figure BDA0005064670590000151 
Figure BDA0005064670590000152 
Figure BDA0005064670590000161
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of priority to U.S. Provisional Application No. 63 / 336,068, filed on April 28, 2022, and U.S. Provisional Application No. 63 / 486,776, filed on February 24, 2023, the contents of which are hereby incorporated by reference in their entirety.
[0003] Reference to a sequence listing
[0004] This application contains a sequence listing, which is electronically submitted in XML format and is hereby incorporated by reference in its entirety. The XML copy was created on April 21, 2023, named AT-052-03WO_ST26.xml, and is 4,366 bytes in size. Background Art
[0005] Chimeric antigen receptor (CAR) T cell therapy has achieved unprecedented success, but the preparation of CAR T cells also faces unprecedented challenges. CAR T cells derived from the patient's own cells (autologous CAR T cells) have disadvantages, including delays in treating patients and the inability to treat all patients due to the failure of preparation caused by the dysfunctional T cells (dysfunctional T cells) present in this patient population. In contrast, compared with autologous CAR T cells, CAR T cells derived from allogeneic donor cells (allogeneic CAR T cells) can be produced as ready-made products, with lower costs and simpler preparation processes. Allogeneic CAR T cell therapy uses T cells from healthy individuals as starting materials, simplifying supply and providing the convenience of ready-made products. The use of healthy donor T cells also opens up the possibility of optimizing therapeutic efficacy and providing more homogeneous products by using immunologically suitable donor T cells. Methods and reagents are needed to identify and select donor T cell populations for the preparation of CAR T cell products. Technical Field
[0006] The present disclosure relates to methods and reagents for analyzing properties of cell populations (e.g., donor cell populations, such as donor immune cell populations and / or engineered cell populations, such as engineered immune cells, e.g., CAR-T cells), selecting suitable donor cell populations for modification to provide engineered donor cell populations (e.g., engineered immune cell populations, such as CAR T cell populations). For example, the present disclosure relates, inter alia, to methods, compositions, and kits for detecting the presence or absence and / or secretion profile of biomarkers of donor cell populations, selecting donor cells having certain biomarkers and / or secretion profiles, and engineering CAR T cells from selected donor cells. Summary of the invention
[0007] The present disclosure relates to methods and reagents for analyzing the properties of donor cell populations before modification to prepare engineered cells (e.g., engineered immune cell populations, such as CAR T cell populations). One or more of the same properties of engineered immune cell populations derived from such donor cell populations can also be analyzed at one or more time points in the engineering process (e.g., CAR-T cell preparation process).
[0008] In one aspect, the present disclosure provides a method for preparing engineered immune cells. In one embodiment, the method includes detecting that the HLA-DR expression level in the immune cell population is 65% or less. In another embodiment, the method further includes modifying the immune cell population to express an exogenous nucleic acid sequence, thereby providing an engineered immune cell population. In a further embodiment, the modification step further includes reducing or eliminating the expression of endogenous genes (e.g., such as TCRα and / or CD52, as further described herein).
[0009] In other embodiments, (i) the exogenous nucleic acid sequence comprises a chimeric antigen receptor (CAR) nucleic acid sequence, or (ii) the exogenous nucleic acid sequence further comprises one or more nucleic acid sequences selected from the group consisting of: a chimeric antigen receptor (CAR), a transmembrane domain nucleic acid sequence, a costimulatory domain nucleic acid sequence, and a signaling domain nucleic acid sequence. In another embodiment, the exogenous nucleic acid sequence is expressed as a single transcript. In an additional embodiment, the CAR nucleic acid sequence expresses a CAR that binds to BCMA, EGFRvIII, WT-1, CD20, CD23, CD30, CD38, CD33, CD133, MHC-WT1, TSPAN10, MHC-PRAME, Liv1, ADAM10, CHRNA2, LeY, NKGD2D, CS1, CD44v6, ROR1, Claudin-18.2, Muc17, FAP alpha, Ly6G6D, c6orf23, G6D, MEGT1, NG25, CD19, FLT3, CD70, DLL3, CD52 or CD34.
[0010] In one embodiment, compared with an unengineered immune cell group, an engineered immune cell group includes, exhibits, displays or has improved in vitro functions. In another embodiment, compared with an additional engineered immune cell group derived from (derived from or derived from) expressing HLA-DR at a level greater than about 65%, an engineered immune cell group includes, exhibits, displays or has improved in vitro functions. In other embodiments, improved in vitro functions include improved in vitro cytotoxicity, improved cell fitness (fitness) and reduced cytokine secretion One or more. In another embodiment, cytotoxicity is demonstrated by in vitro killing assays. In other embodiments, in vitro killing assays include killing cells expressing CAR targets. In vitro killing assays described herein can be long-term killing assays or short-term killing assays.
[0011] In another embodiment, before the detection step, the immune cell population is obtained from or derived from a donor. In one embodiment, the donor is a healthy donor or a patient in need of treatment (e.g., such as a human patient). In another embodiment, the patient is a patient in need of treatment with autologous cell therapy. In another embodiment, the autologous cell therapy comprises an engineered immune cell population.
[0012] In other embodiments, the detecting step comprises detecting the protein level of a molecule (eg, HLA-DR or TIGIT) using flow cytometry (FACS), enzyme-linked immunosorbent assay (ELISA), immunoblotting assay, immunofluorescence assay, or immunochemistry (IHC) assay.
[0013] In one embodiment, the donor from which the immune cell population is obtained or derived prior to the detecting step is a healthy human donor. In another embodiment, the age of the healthy human donor is about 18 to about 30 years old.
[0014] In other embodiments, the method further comprises detecting the expression level of one or more biomarkers selected from the group consisting of: TIGIT, CD16, CD56, CCR7, CD27 and CD45RA. In one embodiment, the method further comprises detecting the expression level of TIGIT. In another embodiment, the TIGIT expression level detected in the immune cell population is 30% or less.
[0015] In an additional embodiment, the method further comprises depleting HLA-DR positive immune cells from the immune cell population to provide an HLA-DR deleted immune cell population, and / or depleting TIGIT positive immune cells from the immune cell population to provide a TIGIT deleted immune cell population. In one embodiment, the depletion step is performed before the modification step.
[0016] In one other aspect, the present disclosure provides an engineered immune cell group comprising certain levels of biomarker-positive cells. In one embodiment, the engineered immune cell group comprises 65% or less HLA-DR+ cells and / or 30% or less TIGIT+ cells. In some embodiments, the engineered immune cell group with biomarker-positive cells comprises an exogenous nucleic acid sequence. In other embodiments, (i) the exogenous nucleic acid sequence comprises a chimeric antigen receptor (CAR) nucleic acid sequence, or (ii) the exogenous nucleic acid sequence further comprises one or more nucleic acid sequences selected from the group consisting of: a chimeric antigen receptor (CAR), a transmembrane domain nucleic acid sequence, a co-stimulatory domain nucleic acid sequence, and a signaling domain nucleic acid sequence. In another embodiment, the exogenous nucleic acid sequence is expressed as a single transcript. In an additional embodiment, the CAR nucleic acid sequence expresses a CAR that binds to BCMA, EGFRvIII, WT-1, CD20, CD23, CD30, CD38, CD33, CD133, MHC-WT1, TSPAN10, MHC-PRAME, Liv1, ADAM10, CHRNA2, LeY, NKGD2D, CS1, CD44v6, ROR1, Claudin-18.2, Muc17, FAP alpha, Ly6G6D, c6orf23, G6D, MEGT1, NG25, CD19, FLT3, CD70, DLL3, CD52 or CD34.
[0017] In another aspect, the present disclosure provides a method for preparing an immune cell with improved in vitro function. In some embodiments, the method comprises the following steps: detecting the HLA-DR expression level in the immune cell population to provide the detected HLA-DR expression level. In some embodiments, the detection includes using flow cytometry (FACS), enzyme-linked immunosorbent assay (ELISA), immunoblotting assay, immunofluorescence assay or immunochemistry (IHC) assay to detect the protein level of HLA-DR. The method may further include the following steps: modifying the immune cell population to express an exogenous nucleic acid sequence, thereby providing an engineered immune cell population. In some embodiments, compared with (i) another engineered immune cell population derived from another immune cell population with a higher HLA-DR expression level than the detected level, (ii) another engineered immune cell population derived from another immune cell population with a higher HLA-DR expression level than the detected level, or (iii) another engineered immune cell population derived from another immune cell population with a higher HLA-DR expression level than the detected level, the engineered immune cell population comprises, exhibits, displays or has improved in vitro function. The method may further include detecting different levels of expression of different biomarkers and combinations thereof. In other embodiments, the detected levels indicate that HLA-DR is expressed in less than 65% of immune cells of an immune cell population. In another embodiment, the lower level is greater than 65% of immune cells of another immune cell population. In one embodiment, the modification step further includes reducing or eliminating the expression or activity of an endogenous gene.
[0018] In some embodiments, the exogenous nucleic acid sequence includes a chimeric antigen receptor (CAR) nucleic acid sequence. The exogenous nucleic acid sequence may further include one or more nucleic acid sequences selected from the group consisting of: transmembrane domain nucleic acid sequence, costimulatory domain nucleic acid sequence and signal transduction domain nucleic acid sequence. In other embodiments, the exogenous nucleic acid sequence is expressed as a single transcript. In some embodiments, the CAR nucleic acid sequence expresses BCMA, EGFRvIII, WT-1, CD20, CD23, CD30, CD38, CD33, CD133, MHC-WT1, TSPAN10, MHC-PRAME, Liv1, ADAM10, CHRNA2, LeY, NKGD2D, CS1, CD44v6, ROR1, Claudin-18.2, Muc17, FAP alpha, Ly6G6D, c6orf23, G6D, MEGT1, NG25, CD19, FLT3, CD70, DLL3, CD52 or CD34 combined CAR.
[0019] In one embodiment, the improved in vitro function of the engineered immune cell group includes, exhibits, displays or has improved in vitro cytotoxicity. The improved in vitro function may include improved in vitro cytotoxicity. In some embodiments, cytotoxicity is demonstrated by in vitro killing assays. In some embodiments, cytotoxicity is demonstrated by in vitro killing assays, and the in vitro killing assays include killing cells expressing the target of CAR. In other embodiments, the in vitro killing assay is a long-term killing assay (LTKA) or a short-term killing assay (STKA).
[0020] In other embodiments, prior to the detection step, the immune cell population is obtained from or derived from a donor. The donor can be a healthy donor or a patient in need of treatment. In one embodiment, the patient is a patient in need of treatment with autologous cell therapy. Autologous cell therapy can include engineered immune cell populations.
[0021] In another aspect, the present disclosure provides a method for selecting a donor immune cell population for engineering. In one embodiment, the method comprises the following steps: detecting a first HLA-DR expression level in a first immune cell population to provide a first detected HLA-DR level. In another embodiment, the method comprises the following steps: detecting a second HLA-DR expression level in a second immune cell population to provide a second detected HLA-DR level. In one other embodiment, the level of the second detection is greater than the level of the first detection. The method may include selecting a first immune cell population for engineering. In some embodiments, the method may further include discarding the second cell population and / or retaining the first cell population. In another embodiment, the detection step includes using flow cytometry (FACS), enzyme-linked immunosorbent assay (ELISA), immunoblot assay, immunofluorescence assay or immunochemistry (IHC) assay to detect the protein level of HLA-DR. In other embodiments, the level of the first detection indicates that HLA-DR is expressed in less than 65% of the immune cells of the immune cell population. In another embodiment, the level of the second detection indicates that HLA-DR is expressed in more than 65% of the immune cells of the immune cell population.
[0022] In one embodiment, the method may further include the steps of modifying the first immune cell population to express an exogenous nucleic acid sequence, thereby providing an engineered immune cell population, in some embodiments, the engineered immune cell population comprises, exhibits, displays or has improved in vitro function compared to another engineered immune cell population derived from (derived from) the second immune cell population. The method may further include detecting different levels of expression of different biomarkers and combinations thereof. In one embodiment, the modification step further includes reducing or eliminating the expression or activity of endogenous genes.
[0023] In some embodiments, the exogenous nucleic acid sequence includes a chimeric antigen receptor (CAR) nucleic acid sequence. The exogenous nucleic acid sequence may further include one or more nucleic acid sequences selected from the group consisting of: transmembrane domain nucleic acid sequence, costimulatory domain nucleic acid sequence and signal transduction domain nucleic acid sequence. In other embodiments, the exogenous nucleic acid sequence is expressed as a single transcript. In some embodiments, the CAR nucleic acid sequence expresses BCMA, EGFRvIII, WT-1, CD20, CD23, CD30, CD38, CD33, CD133, MHC-WT1, TSPAN10, MHC-PRAME, Liv1, ADAM10, CHRNA2, LeY, NKGD2D, CS1, CD44v6, ROR1, Claudin-18.2, Muc17, FAP alpha, Ly6G6D, c6orf23, G6D, MEGT1, NG25, CD19, FLT3, CD70, DLL3, CD52 or CD34 combined CAR.
[0024] In one embodiment, the improved in vitro function of the engineered immune cell population includes improved in vitro cytotoxicity. The improved in vitro function may include improved in vitro cytotoxicity. In some embodiments, cytotoxicity is demonstrated by in vitro killing assays. In some embodiments, cytotoxicity is demonstrated by in vitro killing assays, which in vitro killing assays include killing cells expressing CAR targets. In other embodiments, the in vitro killing assay is a long-term killing assay or a short-term killing assay.
[0025] In other embodiments, prior to the detection step, the immune cell population is obtained from or derived from a donor. The donor can be a healthy donor or a patient in need of treatment. In one embodiment, the patient is a patient in need of treatment with autologous cell therapy. Autologous cell therapy can include engineered immune cell populations.
[0026] In another aspect, the present disclosure provides a method for preparing an immune cell with improved in vitro function. In one embodiment, the method comprises the following steps: modifying an immune cell population to express an exogenous nucleic acid sequence, thereby providing an engineered immune cell population, and the method may further include removing HLA-DR positive engineered immune cells from the engineered immune cell population to provide an engineered immune cell population with HLA-DR removed. In another embodiment, compared to an engineered immune cell population in which HLA-DR positive engineered immune cells are not removed, the engineered immune cell population with HLA-DR removed contains, exhibits, displays or has improved in vitro function. In a further embodiment, the method further includes removing additional immune cells from the engineered immune cell population. In other embodiments, additional immune cells express one or more of TIGIT, CD16 and CD56. In another embodiment, compared to the engineered immune cell population in which HLA-DR is eliminated and TIGIT, CD16 or CD56 is eliminated, the engineered immune cell population in which HLA-DR is eliminated and TIGIT, CD16 or CD56 is eliminated contains, exhibits, shows or has improved in vitro function. In another embodiment, the modification step further includes reducing or eliminating the expression or activity of endogenous genes. In another embodiment, the elimination includes a flow cytometry (FACS) method. In another embodiment, the method further includes detecting the HLA-DR expression level in the engineered immune cell population in which HLA-DR is eliminated, and / or detecting TIGIT, CD16 and / or CD56 levels in the engineered immune cell population in which TIGIT, CD16 and / or CD56 are eliminated.
[0027] In some embodiments, the exogenous nucleic acid sequence includes a chimeric antigen receptor (CAR) nucleic acid sequence. The exogenous nucleic acid sequence may further include one or more nucleic acid sequences selected from the group consisting of: transmembrane domain nucleic acid sequence, costimulatory domain nucleic acid sequence and signal transduction domain nucleic acid sequence. In other embodiments, the exogenous nucleic acid sequence is expressed as a single transcript. In some embodiments, the CAR nucleic acid sequence expresses BCMA, EGFRvIII, WT-1, CD20, CD23, CD30, CD38, CD33, CD133, MHC-WT1, TSPAN10, MHC-PRAME, Liv1, ADAM10, CHRNA2, LeY, NKGD2D, CS1, CD44v6, ROR1, Claudin-18.2, Muc17, FAP alpha, Ly6G6D, c6orf23, G6D, MEGT1, NG25, CD19, FLT3, CD70, DLL3, CD52 or CD34 combined CAR.
[0028] In other embodiments, prior to the detection step, the immune cell population is obtained from or derived from a donor. The donor can be a healthy donor or a patient in need of treatment. In one embodiment, the patient is a patient in need of treatment with autologous cell therapy. Autologous cell therapy can include engineered immune cell populations.
[0029] In one other aspect, the present disclosure provides a chimeric antigen receptor T (CAR-T) cell population. In one embodiment, the CAR-T cell population is a cell population expressing HLA-DR at a first level, and the CAR-T cell population has improved in vitro function compared to a CAR-T cell population expressing HLA-DR at a second level. In other embodiments, the first level is lower than the second level. In another embodiment, the first level is greater than 75% in the CAR-T cell population, and / or wherein the second level is less than 75% in the CAR-T cell population.
[0030] In another embodiment, the CAR-T cell group has an exogenous nucleic acid sequence comprising a chimeric antigen receptor (CAR) nucleic acid sequence. The exogenous nucleic acid sequence may further include one or more nucleic acid sequences selected from the group consisting of: a transmembrane domain nucleic acid sequence, a costimulatory domain nucleic acid sequence, and a signaling domain nucleic acid sequence. In other embodiments, the exogenous nucleic acid sequence is expressed as a single transcript. In some embodiments, the CAR nucleic acid sequence expresses a CAR that binds to BCMA, EGFRvIII, WT-1, CD20, CD23, CD30, CD38, CD33, CD133, MHC-WT1, TSPAN10, MHC-PRAME, Liv1, ADAM10, CHRNA2, LeY, NKGD2D, CS1, CD44v6, ROR1, Claudin-18.2, Muc17, FAP alpha, Ly6G6D, c6orf23, G6D, MEGT1, NG25, CD19, FLT3, CD70, DLL3, CD52, or CD34.
[0031] In one embodiment, the improved in vitro function of the CAR-T cell group includes improved in vitro cytotoxicity. The improved in vitro function may include improved in vitro cytotoxicity. In some embodiments, cytotoxicity is demonstrated by in vitro killing assays. In some embodiments, cytotoxicity is demonstrated by in vitro killing assays, which in vitro killing assays include killing cells expressing CAR targets. In other embodiments, the in vitro killing assay is a long-term killing assay or a short-term killing assay.
[0032] In another aspect, the present disclosure provides a kit or product for in vitro functional analysis of a cell population (e.g., a donor cell population and / or an engineered cell population). In one embodiment, the kit includes an anti-HLA-DR binding agent. The kit may further include instructions for using a binding agent to detect the HLA-DR expression level in the cell population. In other embodiments, the kit further includes one or more additional binding agents to detect one or more of TIGIT, CD16, and CD56. The kit may further include instructions for using a binding agent to detect one or more of the expression levels of TIGIT, CD16, CD56, CCR7, CD27, CD45RA, and any combination thereof in the cell population. In one embodiment, the kit further includes a reagent for measuring the in vitro cytotoxicity of CAR T cells engineered from a cell population. The binding agent may be an antigen binding molecule, which may be an antibody or a fragment thereof. BRIEF DESCRIPTION OF THE DRAWINGS
[0033] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
[0034] Figure 1A-1B Correlations between in vitro CAR T cell function (long-term killing assay or LTKA) and certain biomarkers at the end of CAR-T cell preparation are depicted. Figure 1C-1D Correlations between in vitro CAR T cell function (long-term killing assay or LTKA) and other cell properties (cell fitness and cytokine secretion) were depicted.
[0035] Figure 2A-2B Depicts the observed starting materials ( Figure 2A ) and CAR T cell products ( Figure 2B ) had an inverse correlation with age, with older donors having fewer stem / central memory T cells than younger donors.
[0036] Figure 3A-3B showed that patient-derived CAR T cells tended to have lower Tscm percentages at the end of culture compared with CAR T cells generated from healthy donor material, highlighting the limited fitness of diseased donor T cells ( Figure 3A - Starting materials and Figure 3B – after CAR T preparation).
[0037] Figure 4A-4B T cells from young donors were shown to have a younger T cell phenotype, lower expression of exhaustion markers (e.g., HLA-DR and TIGIT), and better in vitro cytotoxicity.
[0038] Figure 5 Exemplary protocols for isolation of donor cells (e.g., PBMCs), biomarker analysis, activation, transduction, transfection, depletion, expansion, and collection of T cells from isolated donor cells are shown. DETAILED DESCRIPTION
[0039] The present disclosure relates to methods and reagents for analyzing cell populations, such as donor cell populations and / or engineered cell populations, to identify candidates for making engineered cell populations and / or to improve the process of making engineered cell populations.
[0040] Provided herein are methods and reagents for analyzing and / or characterizing cell populations, such as donor cell populations, including but not limited to donor immune cell populations, such as peripheral blood mononuclear cells (PBMCs), for selecting donor cells for preparing engineered cell populations, such as engineered immune cell populations, such as CAR T cell populations. The methods and reagents disclosed herein allow for identification of donor cell populations based on one or more attributes, if any, resulting in improved in vitro function of engineered cell populations derived from the donor cells compared to donor cell populations that do not have one or more attributes. Also provided herein are processes, workflows, kits, articles, and reagents that allow reliable and convenient analysis of key attributes of donor cell populations.
[0041] In addition, the present disclosure provides methods and reagents for analyzing and / or characterizing engineered cell populations (such as engineered immune cell populations, including but not limited to CAR-T cell populations), for use in the preparation of such engineered cell populations. The methods and reagents disclosed herein allow identification of one or more attributes of an engineered cell population, if any, resulting in improved in vitro function of the engineered cell population compared to an engineered immune cell population without one or more attributes. Also provided herein are processes, workflows, kits, products, and reagents that allow reliable and convenient analysis of key attributes of an engineered cell population.
[0042] As used herein, the terms "a" and "an" are used to indicate one or more. For example, reference to a "cell" or "antibody" refers to "one or more cells" or "one or more antibodies".
[0043] As used herein, the term "biomarker-removed" refers to a donor cell or donor cell population from a donor cell population in which an unwanted cell subset expressing one or more biomarkers (e.g., cell surface protein markers) has been separated from an original donor cell population. One or more biomarkers include, but are not limited to, HLA-DR, TIGIT, CD16, CD56, and any combination thereof. According to the methods described herein, a donor cell population (e.g., HLA-DR-removed and / or TIGIT-removed donor cell population) of biomarker removal means a donor cell population that contains fewer cells expressing one or more biomarkers than a donor cell population that does not remove one or more biomarkers. For example, a cell population (or HLA-DR-removed cell) of HLA-DR removal can include 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less than 1% of cells expressing HLA-DR.
[0044] As used herein, the term "labeling agent" generally refers to a reagent that can interact with a cell component, and the cell component includes but is not limited to a cell membrane, a molecule on and / or in a cell, an intracellular molecule of a cell, etc. The interaction between a reagent and a cell component can be a covalent interaction or a non-covalent interaction, a reversible interaction or an irreversible interaction. The labeling agent can be specific to a cell component, and the cell component includes but is not limited to the biomolecules (e.g., polypeptides, nucleic acids, lipids, etc.) of a cell. In some embodiments, the labeling agent can be a reagent that is specific to a biological target, such as an antibody or an antibody fragment. In one embodiment, the labeling agent is a reagent that is specific to a cell surface molecule (e.g., a cell surface or a cell membrane protein). In some cases, the labeling agent can include one or more detectable labels. In some embodiments, the labeling agent includes an antibody, which is optionally conjugated to a detectable label.
[0045] In some embodiments, the detectable label is selected from the group consisting of: fluorescent labels, photochromic compounds, protein fluorescent labels, molecules capable of colorimetric reactions, magnetic labels, radioactive labels, oligonucleotide labels, and haptens. In some embodiments, the fluorescent label is selected from the group consisting of: Atto dyes, Alexafluor dyes, quantum dots, hydroxycoumarins, aminocoumarins, methoxycoumarins, Cascade Blue, Pacific Blue, Pacific Orange, Lucifer Yellow, NBD, R-phycoerythrin (PE), PE-Cy5 conjugates, PE-Cy7 conjugates, Red 613, PerCP, TruRed, FluorX, fluorescein, BODIPY-FL, Cy2, Cy3, Cy3B, Cy3.5, Cy5, Cy5.5. Cy7, TRITC, X-rhodamine, Lissamine Rhocamine B, Texas Red, Allophycocyanin (APC), APC-Cy7 conjugate, Indo-1, Fluo-3, Fluo-4, DCFH, DHR, SNARF, GFP (Y66H mutation), GFP (Y66F mutation), EBFP, EBFP2, Azurite, GFPuv, T-Sapphire, Cerulean, mCFP, mTurquoise2, ECFP, CyPet, GFP (Y66W mutation), mKeima-Red, TagCFP, AmCyan1, mTFP1, GFP (S65A mutation), Midorishi Cyan), wild-type GFP, GFP (S65C mutation), TurboGFP, TagGFP, GFP (S65L mutation), Emerald, GFP (S65T mutation), EGFP, Azami Green, ZsGreen1, TagYFP, EYFP, Topaz, Venus, mCitrine, YPet, TurboYFP, ZsYellow1, Kusabira Orange In some embodiments, the one or more labeling agents are used in flow cytometry. The one or more labels can be coupled or conjugated directly or indirectly to the labeling agent. For indirect forms, the one or more labels can be coupled or conjugated to a molecule that can bind to the labeling agent. For example, a label can be conjugated to an oligonucleotide sequence that is complementary to another oligonucleotide sequence from an oligonucleotide conjugated to a labeling agent (e.g., an antibody conjugated to an oligonucleotide). Labels can also be used with the methods and compositions of the present disclosure in the context of binding agents such as secreted molecule binding agents, e.g., secreted cytokine binding agents.
[0046] Properties of cell populations
[0047] In one aspect, the present disclosure relates to detecting, identifying and / or selecting cells with desired attributes from a cell population (such as donor cells from a donor cell population) before modifying such cells to prepare engineered cells (e.g., before modifying donor cells to prepare CAR T cell products). The methods and reagents disclosed herein allow for identification of donor cell populations (e.g., donor cell populations) based on one or more attributes, if any, and one or more attributes are related to the improved in vitro function of an engineered cell population (e.g., engineered immune cell population) derived from the cell (e.g., donor cell) compared to a cell population without one or more attributes. One or more attributes can be used to screen a cell population (e.g., donor cell population), including but not limited to the presence or absence of one or more biomarkers as described herein. In vitro function can be evaluated in different ways, including but not limited to cytotoxicity, cytokine secretion analysis, and cell fitness (e.g., mitochondrial fitness). In addition, engineered cells derived from donor cells (e.g., engineered immune cells, such as CAR-T cells) can be subjected to the same detection, identification and / or selection methods based on the same or different attributes analyzed in donor cells.
[0048] Biomarker testing
[0049] In one aspect, the present disclosure provides methods and reagents for screening or analyzing cells from a cell population (e.g., donor cells of a donor cell population and / or engineered cells of an engineered cell population) to obtain the percentage of cells expressing one or more biomarkers from the cell population. In one embodiment, the biomarker is one or more of the following: T cell immunoreceptor (TIGIT) with Ig and immunoreceptor tyrosine inhibitory motif (ITIM) domains, human leukocyte antigen-DR isotype (HLA-DR), CD16, CD56, CD27, chemokine receptor 7 (CCR7), CD45RA, and any combination thereof. In another embodiment, the cell is characterized by (a) the percentage of one or more of the following biomarkers: TIGIT, HLA-DR, CD16, CD56, and any combination thereof and / or (b) the percentage of one or more of the following biomarkers: CD27, CCR7, CD45RA, and any combination thereof.
[0050] In other embodiments, the percentage of detection of cells expressing biomarkers described herein (e.g., HLA-DR, TIGIT, CD16, CD56, CD27, CCR7, CD45RA, and any combination thereof) is about 0% to about 100% of the analyzed cell population. In other embodiments, the percentage of cells expressing biomarkers is about 0%, about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 8 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100%.
[0051] In one aspect, methods, compositions, cell populations and kits relate to detecting, identifying and / or screening cells (donor cells and / or engineered cells) from a cell population (e.g., a donor cell population and / or an engineered cell population) for obtaining HLA-DR expression levels as a percentage in the tested cell population. Certain percentages of certain biomarkers in certain cell populations can predict the in vitro functional extent of engineered immune cells in an engineered immune cell population (e.g., a CAR-T cell population) of donor cells derived from a donor cell population.
[0052] In one embodiment, the donor cells of the donor cell group are obtained from a human donor of a young donor. A young donor is a donor whose age is about 30 years old or less. In other embodiments, the age of the young donor is about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29 or about 30 years old. In one other embodiment, the donor is about 18 to about 30 years old, about 18 to about 29 years old, about 19 to about 30 years old or about 19 to about 29 years old. In one other embodiment, the HLA-DR expression in the donor cell group from a young donor is lower than the HLA-DR expression in the donor cell group from a donor whose age is greater than 30 years old.
[0053] In one embodiment, the level shows that HLA-DR is expressed in less than 65% of the cells of the cell group. In another embodiment, <65% of the cells are related to the improved in vitro function (e.g., cytotoxicity) of the cell group (such as the immune cell group through engineering). In one other embodiment, the level shows that HLA-DR is expressed in more than 65% of the cells of the cell group.<65% of the colony shows stronger in vitro function (e.g., cytotoxicity) than>65% of the colony. In other embodiments, the percentage of HLA-DR expressing cells related to the improved in vitro function (e.g., cytotoxicity) of the cell group can be detected within a certain percentage range. In one embodiment, the <65% percentage range of HLR-DR expressing cells can be about 30% to about 35%, about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, or about 55% to about 60%. In another embodiment, the <65% level of HLR-DR expressing cells is about 60%, about 61%, about 62%, about 63%, about 64%, or about 64.5%.
[0054] In one other embodiment, the percentage range of HLR-DR expressing cells can be detected as 65% or greater, which is not as preferred as less than 65%. In another embodiment, such cells can express HLA-DR at a level of about 65% to about 90%, about 70% to about 85%, about 75% to about 80%, about 65% to about 70%, about 65% to about 75%, about 70% to about 75%, about 85% to about 90%, about 80% to about 90%, or about 75% to about 90%. In one embodiment, if the detected HLA-DR level is greater than 90%, the cell is not used in the methods described herein.
[0055] Other levels of additional biomarkers can be analyzed. In another embodiment, the level of TIGIT expression is detected as a percentage in the tested cell population. In one embodiment, the level indicates that TIGIT is expressed in less than 30% of the cells of the cell population. In one embodiment, <30% of TIGIT expressing cells are associated with improved in vitro functions (e.g., cytotoxicity) of a cell population (such as an engineered immune cell population). In another embodiment, the level indicates that TIGIT is expressed in more than 30% of the cells of the cell population. <30% of the population exhibits stronger in vitro functions (e.g., cytotoxicity) than >30% of the population. In other embodiments, the percentage of TIGIT expressing cells associated with improved in vitro functions of a cell population (e.g., engineered immune cells) can be detected within a certain percentage range. In one embodiment, the <30% percentage range of TIGIT expressing cells can be about 1% to about 5%, about 5% to about 10%, about 10% to about 15%, about 15% to about 20%, or about 20% to about 25%. In another embodiment, the level of <30% of TIGIT expressing cells is about 26%, about 27%, about 28%, about 29%, or about 29.5%.
[0056] In one other embodiment, the percentage range of TIGIT expressing cells can be detected as 30% or greater, which is not as preferred as less than 30%. In another embodiment, such cells can express TIGIT at a level of about 30% to about 55%, about 35% to about 50%, about 40% to about 45%, about 30% to about 35%, about 30% to about 40%, about 30% to about 45%, about 50% to about 55%, about 45% to about 55%, or about 50% to about 55%. In one embodiment, if the detected HLA-DR level is greater than 55%, the cell is not used in the methods described herein.
[0057] In another embodiment, the level of CD16 expression is detected as a percentage in the tested cell population. In one embodiment, the level shows that CD16 is expressed in less than 4% of the cells of the cell population. In another embodiment, <4% of the cells are related to the improved in vitro function (e.g., cytotoxicity) of the cell population (such as an engineered immune cell population). In another embodiment, the level shows that CD16 is expressed in more than 4% of the cells of the cell population. <4% of the population shows a stronger in vitro function (e.g., cytotoxicity) than >4% of the population. In other embodiments, the percentage of CD16 expressing cells related to the improved in vitro function (e.g., cytotoxicity) of the cell population can be detected within a certain percentage range. In one embodiment, the <4% percentage range of CD16 expressing cells can be about 0.5%, about 1%, about 1.5%, about 2%, about 2.5%, about 3%, about 3.5%, or about 3.75%.
[0058] In another embodiment, the percentage range of CD16 expressing cells can be detected as greater than 4%, which is not as preferred as less than 4%. In another embodiment, such cells can express CD16 at a level of about 4% to about 10%, about 5% to about 9%, about 6% to about 8%, about 4% to about 5%, about 4% to about 6%, about 4% to about 7%, about 4% to about 8%, about 4% to about 9%, or about 9% to about 10%, about 8% to about 10%, about 7% to about 10%, about 6% to about 10%, or about 5% to about 10%. In one embodiment, if the CD16 level detected is greater than 10%, the cell is not used in the methods described herein.
[0059] In a further embodiment, the level of CD56 expression is detected as a percentage in the tested cell population. In one embodiment, the level indicates that CD56 is expressed in less than 15% of the cells of the cell population. In another embodiment, <15% of the cells are associated with improved in vitro functions (e.g., cytotoxicity) of a cell population (such as an engineered immune cell population). In another embodiment, the level indicates that CD56 is expressed in greater than 15% of the cells of the cell population. The <15% population exhibits stronger in vitro functions (e.g., cytotoxicity) than the >15% population. In other embodiments, the percentage of CD56 expressing cells associated with improved in vitro functions (e.g., cytotoxicity) of a cell population can be detected within a certain percentage range. In one embodiment, the <15% percentage range of CD56 expressing cells can be about 1% to about 5% or about 5% to about 10%. In another embodiment, the level of <15% of CD56 expressing cells is about 11%, about 11.5%, about 12%, about 12.5%, about 13%, about 13.5%, about 14%, about 14.5%, or about 14.75%.
[0060] In another embodiment, the percentage range of CD56 expressing cells can be detected as greater than 15%, which is less than 15% preferred. In another embodiment, such cells can express CD56 at a level of about 15% to about 20%, about 16% to about 19%, about 17% to about 18%, about 15% to about 16%, about 15% to about 17%, about 15% to about 18%, about 15% to about 19%, about 19% to about 20%, or about 18% to about 20%, about 17% to about 20%, about 18% to about 20%, or about 19% to about 20%. In one embodiment, if the CD56 level detected is greater than 20%, the cell is not used in the methods described herein.
[0061] In another embodiment, the level of CCR7 expression is detected as the percentage in the tested cell group. In one embodiment, the level shows that CCR7 is expressed in cells greater than 30% of the cell group. In another embodiment, >30% of the cell is related to the improved in vitro function (e.g., cytotoxicity) of the cell group (such as the immune cell group through engineering). In another embodiment, the level shows that CCR7 is expressed in cells less than 30% of the cell group. >30% of the colony shows stronger in vitro function (e.g., cytotoxicity) than <30% of the colony. In other embodiments, the percentage of CCR7 expressing cells related to the improved in vitro function (e.g., cytotoxicity) of the cell group can be detected within a certain percentage range. In one embodiment, the >30% percentage range of CCR7 expressing cells can be about 35% to about 40%, about 40% to about 45%, about 45% to about 50%, about 50% to about 55%, about 55% to about 60%, about 60% to about 65%, or about 65% to about 70%. In another embodiment, the level of >30% of CCR7 expressing cells is about 30.5%, about 31%, about 32%, about 33%, or about 34%.
[0062] In another embodiment, the percentage range of CCR7 expressing cells can be detected as less than 30%, which is not as preferred as being greater than 30%. In one other embodiment, the percentage range of <30% of CCR7 expressing cells can be about 15% to about 30%, about 20% to about 25%, about 15% to about 20%, about 20% to about 25%, about 15% to about 25%, about 25% to about 30%, or about 20% to about 30%. In one embodiment, if the CCR7 level detected is less than 15%, the cell is not used in the method described herein.
[0063] In one other embodiment, the level of CD27 expression is detected as a percentage in the tested cell population. In one embodiment, the level shows that CD27 is expressed in cells greater than 55% of the cell population. In another embodiment, >55% of the cells are related to the improved in vitro function (e.g., cytotoxicity) of the cell population (such as an engineered immune cell population). In one other embodiment, the level shows that CD27 is expressed in cells less than 55% of the cell population. >55% of the population shows stronger in vitro function (e.g., cytotoxicity) than <55% of the population. In other embodiments, the percentage of CD27 expressing cells related to the improved in vitro function (e.g., cytotoxicity) of the cell population can be detected within a certain percentage range. In one embodiment, the >55% percentage range of CD27 expressing cells can be about 60% to about 65%, about 65% to about 70%, about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, or about 90% to about 95%. In another embodiment, the level of >55% of CD27 expressing cells is about 55.5%, about 56%, about 57%, about 58%, or about 59%.
[0064] In another embodiment, the percentage range of CD27 expressing cells can be detected as less than 55%, which is not as preferred as greater than 55%. In another embodiment, such cells can express CD27 at a level of about 30% to about 55%, about 35% to about 50%, about 35% to about 45%, about 30% to about 35%, about 30% to about 40%, about 30% to about 45%, about 30% to about 50%, about 50% to about 55%, about 45% to about 55%, about 40% to about 55%, or about 35% to about 55%. In one embodiment, if the level of CD27 detected is less than 30%, the cell is not used in the methods described herein.
[0065] In a further embodiment, the level of CD45RA expression is detected as a percentage in the tested cell population. In one embodiment, the level indicates that CD45RA is expressed in more than 70% of the cells of the cell population. In another embodiment, >70% of the cells are associated with improved in vitro functions (e.g., cytotoxicity) of a cell population (such as an engineered immune cell population). In another embodiment, the level indicates that CD45RA is expressed in less than 70% of the cells of the cell population. >70% of the population exhibits stronger in vitro functions (e.g., cytotoxicity) than <70% of the population. In other embodiments, the percentage of CD45RA-expressing cells associated with improved in vitro functions (e.g., cytotoxicity) of a cell population can be detected within a certain percentage range. In one embodiment, the >70% percentage range of CD45RA-expressing cells can be about 75% to about 80%, about 80% to about 85%, about 85% to about 90%, or about 90% to about 95%. In another embodiment, the level of >70% of CD45RA expressing cells is about 70.5%, about 71%, about 72%, about 73%, or about 74%.
[0066] In another embodiment, the percentage range of CD45RA expressing cells may be detected as less than 70%, which is less preferred than greater than 70%. In one other embodiment, such cells may express CD45RA at a level of about 50% to about 70%, about 55% to about 65%, about 55% to about 60%, about 50% to about 55%, about 50% to about 60%, about 50% to about 65%, about 65% to about 70%, about 60% to about 70%, or about 55% to about 70%. In one embodiment, if the level of CD45RA detected is less than 50%, the cell is not used in the methods described herein.
[0067] Tables 1-10 present non-limiting examples of different biomarker profiles of cells of a cell population (e.g., donor cells of a donor cell population and / or engineered cells of an engineered cell population) that can be detected using the methods described herein. An asterisk (*) indicates that a biomarker can be detected in the following percentages of cells of a cell population.
[0068] HLA-DR: <65% or between 65% and 90%;
[0069] TIGIT: <30% or between 30% and 55%;
[0070] CD16: <4% or between 4% and 10%;
[0071] CD56: <15% or between 15% and 20%;
[0072] CCR7: >30% or between 15% and 30%;
[0073] CD27: >55% or between 30% and 55%; and
[0074] CD45RA: >70% or between 50%-70%.
[0075] For example, cell biomarker profile #3 in Table 1 corresponds to cells (e.g., donor cells of a donor cell population and / or engineered cells of an engineered cell population) having the following expression percentages of the following biomarkers: HLA-DR: <65% or between 65%-90% and TIGIT: <30% or between 30%-55%. In another example, cell biomarker profile #12 in Table 1 corresponds to cells (e.g., donor cells of a donor cell population and / or engineered cells of an engineered cell population) having the following expression percentages of the following biomarkers: TIGIT: <30% or between 30%-55%.
[0076] Table 1
[0077] 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 HLA-DR * * * * * * * TIGIT * * * * * * * * CD16 * * * * * * * CD56 * * * * * * *
[0078] Table 2
[0079] 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 CD27 * * * * * * * * * * * * * * * HLA-DR * * * * * * * TIGIT * * * * * * * CD16 * * * * * * CD56 * * * * * * * *
[0080] Table 3
[0081] 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 CCR7 * * * * * * * * * * * * * * * HLA-DR * * * * * * * TIGIT * * * * * * * CD16 * * * * * * CD56 * * * * * * * *
[0082] Table 4
[0083] 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 CD45RA * * * * * * * * * * * * * * * HLA-DR * * * * * * * TIGIT * * * * * * * CD16 * * * * * * CD56 * * * * * * * *
[0084] Table 5
[0085]
[0086] Table 6
[0087]
[0088]
[0089] Table 7
[0090]
[0091] Table 8
[0092]
[0093] Table 9
[0094]
[0095] Table 10
[0096] 121 122 123 124 125 126 CD27 * * * * CCR7 * * * CD45RA * * *
[0097] One or more biomarkers of cells from a cell population (e.g., donor cells from a donor cell population and / or engineered cells from an engineered cell population) can be detected using various methods, including but not limited to flow cytometry, fluorescence activated cell sorting, (FACS) flow cytometry, enzyme-linked immunosorbent assay (ELISA), enzyme-linked immunofiltration assay (ELIFA), immunoblot assay, immunofluorescence assay, immunochemistry (IHC) assay, protein blot analysis and immunoprecipitation, molecular binding assay.
[0098] Detection using flow cytometry. Instruments for particle analysis (e.g., flow cytometers and scanning cytometers) allow the use of optical parameters (such as light scattering and fluorescence) to characterize individual particles or cells (e.g., a single donor cell from a donor cell population and / or a single engineered cell from an engineered cell population). For example, a flow cytometer allows an aqueous suspension containing individual particles (e.g., beads containing a target analyte) or cells to pass through a detection area that exposes the suspension to an excitation light source, such as one or more lasers, thereby enabling the user to measure the light scattering and fluorescence properties of the particles or cells. Labeling particles or cells with one or more fluorescent dyes can aid in detection. Different particles or cells can be labeled using different dyes with different spectra, allowing multiple different particles or cells to undergo flow cytometry for simultaneous detection. In other embodiments, multiple photodetectors can be deployed to measure different scattering parameters and / or different spectrally different dyes. For example, one or more detectors can be configured to measure one or more groups of scattering parameters, and one or more additional detectors can be configured to measure one or more different dyes, which will allow data to be generated including signals for each light scattering parameter and each fluorescent emission.
[0099] Flow cytometry parameters that are typically measured include, but are not limited to, (i) excitation light scattered by particles or cells in a mostly forward direction, or forward scatter (FSC), (ii) excitation light scattered by particles or cells in a mostly lateral direction, or side scatter (SSC), and (ii) light emission from fluorescent molecules in one or more channels (frequency ranges) of the spectrum or light emission from fluorescent dyes that are predominantly detected in that channel. In one embodiment, different cell types from a donor cell population can be identified by FSC, SSC, and fluorescent emission caused by labeling various cell surface proteins on the donor cells with dye-labeled antibodies.
[0100] The data obtained by multicolor flow cytometry from analyzing particles or cells (e.g., a single donor cell from a donor cell group and / or a single engineered cell from an engineered cell group) are multidimensional, wherein each cell corresponds to a point in a multidimensional space defined by the measured parameters. Cells or particle groups are identified as clusters of points in the data space. Clustering and group identification can be performed manually by drawing a gate around the group displayed in one or more 2-dimensional graphs (referred to as "scatter plots" or "dot plots") of the data. Alternatively, clusters can be identified, and the gates defining group restrictions can be automatically determined. Flow cytometry is an important tool for analyzing and / or separating particles or cells (e.g., a separate donor cell from a donor cell group) and cell analytes or their components. Therefore, it can be used in the case of donor cell analysis and / or separation. In one embodiment, the present disclosure provides a method for linearly spacing donor cells from a donor cell group using a fluid stream so that they pass through a detection device individually. Individual cells from a donor cell group can be distinguished from other cells by their position in the fluid stream and the presence of a detectable marker. As a result, flow cytometry can be used to detect one or more biomarkers (as described herein) and / or generate a biomarker profile of a donor cell population and / or an engineered cell population. Such a profile can include the percentage of cells expressing one or more biomarkers (as further described herein) in the total cell population analyzed.
[0101] In another aspect, the present disclosure provides a method for detecting cells from a cell group (e.g., donor cells from a donor cell group and / or engineered cells from an engineered cell group) by detecting the level of one or more cell surface biomarkers. In one embodiment, the level of detection indicates that some cells (e.g., donor cells and / or engineered cells) express one or more cell surface biomarkers. In other embodiments, the level of detection indicates that some cells express the first biomarker and / or some cells express the second biomarker. In some embodiments, cells express one or more cell surface markers HLA-DR, TIGIT, CD16, CD56, CCR7, CD27, CD45RA or any combination thereof. In another aspect, the level of one or more biomarkers detected indicates the number of cells (e.g., donor cells and / or engineered cells) expressing one or more biomarkers in the analyzed cell group (e.g., donor cell group and / or engineered cell group). Tables 1-10 above provide additional biomarker profiles of donor cells of donor cell groups.
[0102] In some embodiments, the method provides quantitative measurement of donor cells from a donor cell population that do not express cell surface biomarkers (e.g., HLA-DR, TIGIT, CD16, CD56, CCR7, CD27, CD45RA, or any combination thereof). Flow cytometry can be used to quantitatively express or not express cells of a specific surface marker, or to quantitatively measure cells of a specific cell type in a cell population.
[0103] As described herein, flow cytometry is a method for quantifying components or structural features of cells using certain markers (as further described herein), primarily by optical means. Since different cell types can be distinguished by quantifying structural features, flow cytometry and cell sorting can be used to count and sort cells of different phenotypes in a mixture. Flow cytometry analysis involves two main steps: 1) marking the selected cell type with one or more detectable markers or reagents, and 2) determining the number of labeled cells relative to the total number of cells in the population. In some embodiments, the method of labeling cell types includes binding a labeled antibody to a marker expressed by a specific cell type. The antibody can be directly labeled with a fluorescent compound or indirectly labeled using, for example, a fluorescently labeled second antibody that recognizes the first antibody.
[0104] In one other aspect, the present disclosure utilizes flow cytometry to provide a method for generating a biomarker spectrum of a cell group (e.g., a donor cell group or an engineered cell group) based on the percentage of one or more biomarkers detected. In one embodiment, the method includes providing a donor cell group suspected of containing one or more biomarkers, such as a donor immune cell group. In another embodiment, the method further includes detecting the level of a first biomarker in the donor cell group, wherein the first biomarker level detected indicates that a certain percentage of the donor cell group expresses the first biomarker. In other embodiments, the first biomarker is HLA-DR. In other embodiments, the method further includes detecting the level of a second biomarker in the donor cell group, wherein the second biomarker level detected indicates that a certain percentage of the donor cell group expresses the second biomarker. In an additional embodiment, the second biomarker is TIGIT. In some embodiments, the method includes detecting the level of the first biomarker and the second biomarker, wherein the level detected indicates the expression percentage of the first biomarker and the second biomarker in the donor cell group. In other embodiments, one or more additional biomarkers, such as a third, fourth, fifth, sixth, seventh, etc. biomarker, are detected to determine the percentage of expression of the one or more additional biomarkers in the donor cells of the donor cell population.
[0105] In some embodiments, the method for generating a biomarker spectrum further includes the following steps: modifying or selecting a donor cell group for modification, the donor cell group has undergone biomarker spectrum generation, such as by using flow cytometry. In one embodiment, the method further includes modifying the donor cell group to express an exogenous nucleic acid sequence, so as to provide an engineered immune cell group. In another embodiment, compared with an additional engineered immune cell group derived from (or derived from) expressing a certain percentage of a first biomarker (e.g., HLA-DR) and / or expressing a certain percentage of a second biomarker (e.g., TIGIT), the engineered immune cell group includes, exhibits, displays or has improved in vitro function. The engineered immune cell group can express a certain percentage of two or more biomarkers, such as two or more of HLA-DR, TIGIT, CD16, CD56 and any combination thereof. In other embodiments, exogenous nucleic acid includes a chimeric antigen receptor (CAR) nucleic acid sequence. CAR sequence may include one or more nucleic acid sequences, including but not limited to transmembrane domain nucleic acid sequences, costimulatory domain nucleic acid sequences and signal transduction domain nucleic acid sequences. In one embodiment, the exogenous nucleic acid sequence is expressed as a single transcript. In addition to the modification of the expression of the exogenous nucleic acid sequence or independently of the modification of the expression of the exogenous nucleic acid sequence, the method may further include reducing or eliminating endogenous genes (eg, T cell receptor genes (eg, TCRα, TCRβ) and / or CD52) expression or activity, as further described herein.
[0106] Prior to engineering, an immune cell population as described herein can be obtained from a donor and / or derived from a donor prior to any biomarker detection step. In some embodiments, the donor is a healthy donor or a patient in need of treatment. A patient in need of treatment may require treatment with autologous cell therapy. In one embodiment, an autologous cell therapy may comprise an engineered immune cell population derived from donor cells obtained from a patient.
[0107] As described herein, the engineered cell population with a detected biomarker profile is characterized by improved in vitro function, which can be improved in vitro cytotoxicity and / or improved in vitro cell fitness, such as in vitro mitochondrial fitness. Cytotoxicity can be demonstrated by in vitro killing assays, such as in vitro killing assays including killing cells expressing target molecules recognized by CAR. In vitro killing assays can be in vitro short-term killing assays (STKA) or in vitro long-term killing assays (LTKA).
[0108] In an additional embodiment, the engineered immune cell population exhibits improved in vitro cytotoxicity, as shown by an increased area under the curve or AUC. As used herein, the term "area under the curve" or "AUC" refers to a quantitative measure of the persistence (assay duration) and cytotoxicity (% killing) of LTKA. In the context of STKA, "AUC" refers to a quantitative measure of cytotoxicity at different tumor loads (with an interval of 1 between different effector to target ratios). STKA and LTK AUC can be measured as described in Example 2.
[0109] In other embodiments, the increased AUC is relative to the observed AUC of an engineered immune cell population derived from a non-healthy donor, e.g., a subject with a disease such as cancer. In some embodiments, the AUC is STKA U C or LTKA AUC. In other embodiments, the LTKA AUC is about 749 to about 1217. In another embodiment, the LTKA AUC is about 200 to about 1500, about 225 to about 1475, about 225 to about 1475, about 250 to about 1450, about 275 to about 1425, about 300 to about 1400, about 325 to about 1375, about 325 to about 1350, about 350 to about 1325, about 350 to about 1300, about 375 to about 1275, about 400 to about 1250, about 375 to about 1225, about 400 to about 1250, about 425 to about 1275, about 450 to about 1200, about 475 to about 1175, about 500 to about 1150, about 525 to about 1125, about 550 to about 1100, about 575 to about 1075, about 600 to about 1050, or about 625 to about 1025. In other embodiments, the LTKA AUC is about 700 to about 1250, about 725 to about 1250, about 750 to about 1250, about 775 to about 1250, about 800 to about 1250, about 825 to about 1250, about 850 to about 1250, about 875 to about 1250, about 900 to about 1250, about 925 to about 1250, about 950 to about 1250, about 975 to about 1250, about 1000 to about 1250, about 1025 to about 1250, about 1050 to about 1250, about 1075 to about 1250, about 1100 to about 1250, about 1125 to about 1250, about 1150 to about 1250, about 1175 to about 1250, about 1200 to about 1250, or about 1225 to about 1250. In some embodiments, the LTKA AUC is at least about 1100, at least about 1125, at least about 1150, at least about 1175, at least about 1200, at least about 1225, at least about 1250, at least about 1275, at least about 1300, at least about 1325, at least about 1350, at least about 1375, at least about 1400, at least about 1425, at least about 1450, at least about 1475, or at least about 1500.
[0110] In another embodiment, the AUC is the STKA AUC. In one embodiment, the STKA AUC is about 209 to about 519.
[0111] In another embodiment, the in vitro function is in vitro cell fitness, such as mitochondrial fitness. Mitochondrial fitness can be measured by spare respiratory capacity (SRC), as described in Example 2. In one embodiment, the engineered immune cell group shows improved mitochondrial fitness, as shown by increased SRC. In other embodiments, the increased SRC is relative to the observed SRC of the engineered immune cell group derived from a non-healthy donor (e.g., a subject suffering from a disease (such as cancer)). In some embodiments, SRC is about 27 to about 59. In another embodiment, SRC is about 25, about 30, about 35, about 40, about 45, about 50, about 55, about 60, about 65, about 70, about 75, about 80, about 85, about 90, about 95 or about 100.
[0112] Enrichment or elimination. In one other aspect, the present disclosure provides methods and compositions for enriching and / or eliminating cells (e.g., donor cells from a donor cell population and / or engineered cells from an engineered cell population) from a cell population based on the observed correlation (positive or negative) between the biomarkers described herein and the in vitro functions of engineered cells (e.g., CAR T cells) derived from such donor cells. In one embodiment, a method for elimination or enrichment is provided, comprising the following steps: providing donor cells from a donor cell population, wherein the donor cells include cells expressing one or more of the following cell surface biomarkers: HLA-DR, TIGIT, CD16, CD56, CD27, CCR7, CD45RA, and any combination thereof. Tables 1-10 provide different biomarker profiles for such donor cells. In another embodiment, the method further includes eliminating or removing cells expressing one or more of the following cell surface biomarkers from donor cells: HLA-DR, TIGIT, CD16, CD56, and any combination thereof. In other embodiments, the method further comprises enriching or retaining cells from the donor cells that express one or more of the following cell surface biomarkers: CD27, CCR7, CD45RA, and any combination thereof.
[0113] According to the present disclosure, flow cytometry methods can be used to enrich and / or remove cells from donor cells. Separation of particles or cells (e.g., donor cells from a donor cell population and / or engineered cells from an engineered cell population) can be achieved by adding sorting or collection functions to a flow cytometer. Particles or cells spaced apart in a fluid stream can be detected as having one or more desired features, and are subsequently separated based on the features of the detection of each individual particle or cell. Particles or cells can be separated individually from a stream by mechanical or electrical removal.
[0114] In one aspect, the present disclosure provides methods and reagents for removing unwanted cells (e.g., unwanted donor cells from a donor cell population and / or unwanted engineered cells from an engineered cell population) from a cell population during a cell elimination process. Unwanted cells can be eliminated based on the expression of one or more biomarkers that are less relevant to their in vitro function. Initially, cells from a cell population are exposed to one or more biomarker elimination reagents. In some embodiments, the biomarker elimination reagent comprises an antibody targeting a biomarker expressed on the surface of a donor cell (e.g., a cell surface protein such as HLA-DR, TIGIT, CD16, CD56, and any combination thereof).
[0115] Anti-biomarker antibodies or any other antibodies can be, for example, conjugated to biotin to facilitate further labeling and / or separation using a secondary antibody (e.g., an anti-biotin antibody). The secondary antibody can be directly or indirectly conjugated to a magnetic rejection agent, such as a magnetic rejection agent, such as a magnetic microbead (usually but not necessarily a nanoparticle with a diameter of about 50 nm) or any other surface, such as agarose beads, acoustic wave particles, plastic well plates, glass well plates, ceramic well plates, columns, cell culture bags or membranes. When using magnetic microbeads, the microbeads help separate biomarker-positive cells from biomarker-negative cells; when in contact with a magnetic column, biomarker-positive cells can be retained on the column, while unlabeled biomarker-negative cells pass through a collection bag. When exposed to sound waves, acoustic wave particles can help separate biomarker-positive cells from biomarker-negative cells. Although anti-biotin antibodies are provided in the context of the disclosed methods, other biotin binding partners (such as streptavidin, avidin, and other proteins that recognize biotin) can be employed in place of anti-biotin antibodies in all methods provided herein.
[0116] In some embodiments, the anti-biomarker antibody specific for the biomarker is optionally conjugated to a fluorophore. In this embodiment, the step of sorting or selecting donor cells bound to the antibody (e.g., monoclonal antibody) can be accomplished by fluorescence activated cell sorting (FACS).
[0117] In some other embodiments, anti-biomarker antibodies specific for the biomarker are optionally conjugated to magnetic particles. In this embodiment, the step of sorting or selecting cells bound to the antibody (e.g., monoclonal antibody) can be accomplished by magnetic activated cell sorting (MACS).
[0118] In some embodiments of the disclosed method, magnetic activated cell sorting (MACS) can be used to achieve sorting or separation of biomarker positive cells from biomarker negative cells. Magnetic activated cell sorting is a method for separating various cell populations according to cell surface antigens (CD molecules) by using superparamagnetic nanoparticles and columns. MACS can be used to obtain very pure donor cell populations. Donor cells from donor cell populations in single cell suspensions can be magnetically labeled with microbeads. The sample is applied to a column consisting of ferromagnetic material, which is covered with a coating that does not destroy cells, thereby allowing cells to be separated quickly and gently. Unlabeled cells pass through the column, and magnetically labeled cells remain in the column. Flow-through can be collected as an unlabeled cell portion. After the washing step, the column is taken out from the separator, and magnetically labeled cells are eluted from the column.
[0119] In some embodiments of the disclosed method, acoustic wave separation can be used instead of magnetic-based separation methods to achieve sorting or separation of biomarker-positive cells from biomarker-negative cells. Although it is not desired to be bound by theory, it should be understood that acoustic wave separation relies on three-dimensional standing waves to separate the components of the mixture. In the context of the disclosed method, anti-biomarker antibodies (such as antibodies specific to one or more biomarkers (e.g., HLA-DR, TIGIT, CD16, or CD56)) can be conjugated to a surface, such as acoustic wave particles. Acoustic wave particles can be beads. In one embodiment, donor cells from a donor cell population are exposed to acoustic wave particles with one or more anti-biomarker antibodies (associating acoustic wave particles with any cells expressing the target target). The cells are then placed in an acoustic chamber and exposed to acoustic waves. In view of the different properties of cells associated with beads and cells not labeled with antibody-bead particles, acoustic waves separate labeled and unlabeled cells, which can be collected, while labeled cells (e.g., biomarker-positive cells) can be separated from unlabeled cells.
[0120] In some embodiments, cells are analyzed for other surface markers to indicate different cell types in a cell population, e.g., effector cells, effector memory cells, central memory cells, stem central memory cells, etc., based on widely accepted specific surface markers for each cell type. In another aspect, methods for detecting surface markers indicating other attributes of donor cells from a donor cell population are provided herein. In some embodiments, donor cells are analyzed for other surface markers, the levels of which can indicate the effectiveness or function of the cells. The analysis can be qualitative or quantitative.
[0121] Cytokine analysis
[0122] In one aspect, the present disclosure provides methods and reagents for analyzing the cytokine secretion profile of cells from a cell population (e.g., donor cells from a donor cell population and / or engineered cells from an engineered cell population). Measuring secreted proteins (such as cytokines) from cells of a cell population can provide information about cell properties, which may contribute to and / or be associated with the effects of in vitro functions of modified or engineered cells (e.g., CAR T cells) derived from donor cells. As described herein, flow cytometry methods can be used to generate secreted protein profiles, such as cytokine secretion profiles, at a single cell level. For example, a standard "cytokine secretion assay" (CSA) can be used to provide a cytokine secretion profile, wherein the target secreted cytokines are characterized by using cell surface markers that are specific to the components of cells from a cell population. For example, bifunctional antibodies (e.g., bispecific to cell surface markers and cytokines) can be used to stain cells and "capture" secreted cytokines on the cell surface. Cells can then be stained with fluorescently labeled antibodies that are specific to the captured cytokines. The stained cells were then analyzed using fluorescence activated cell sorting (FACS) to detect cytokines at the single cell level.
[0123] Single cell functional phenotypes (such as secretome profiles, e.g., cytokine secretion profiles) can be generated using discrete fluid chambers and multiplex enzyme-linked immunosorbent assay (ELISA) cytokine capture reagents (e.g., using the IsoCode chip of the IsoLight system (Isoplexis)). In one aspect, the present disclosure provides methods and reagents for generating cytokine secretion profiles of cells of a cell population (e.g., donor cells of a donor cell population and / or engineered cells of an engineered cell population). In one embodiment, the method includes distributing cells from a cell population to a series of separate chambers (e.g., holes, grooves, cavities, depressions, channels, etc.), wherein the chamber (in a series of chambers) contains one or more first cytokine binding agents, e.g., first antibodies specific to different cytokines, for capturing cytokines secreted by cells (e.g., donor cells from a donor cell population and / or engineered cells from an engineered cell population). In other embodiments, the chamber is configured to accommodate a single cell. Optionally, the method includes contacting the cell with an activator before distribution. In one embodiment, one or more first cytokine binding agents are arranged or arranged on the surface (e.g., plane) of the chamber and are configured to capture cytokines secreted by cells in the chamber. In another embodiment, the method includes allowing the partition (e.g., chamber) containing cells to experience conditions that allow one or more first cytokine binding agents to be combined with cytokines secreted by cells. In other embodiments, the method further includes taking out cells from the chamber while retaining one or more secreted cytokines combined with one or more first cytokine binding agents arranged on the surface. The method may further include contacting the combined secreted cytokines with one or more second cytokine binding agents (e.g., a second antibody specific to one or more combined secreted cytokines) under conditions sufficient to allow one or more second cytokine binding agents to be combined. In other embodiments, one or more second cytokine binding agents include one or more labels (as further described herein in the context of labeling agents). Such labels can be used to detect binding events, such as the combination of a fluorescently labeled second cytokine binding agent with a combined secreted cytokine in the chamber, thereby providing a cytokine secretion profile of cells from a cell population. Additional details of methods and compositions are provided in Paczkowski et al. WO / 2016 / 090148, which is incorporated herein by reference in its entirety. The cytokine secretion profile can be expressed as a polyfunctional index (PSI).
[0124] In another embodiment, the engineered immune cell group described herein is characterized by improved in vitro function, wherein the improved in vitro function includes the cytokine secretion of reduction.Cytokine secretion can be measured by multifunctional index score (PSI), as described in Example 2.In one embodiment, the engineered immune cell group shows reduced cytokine secretion, as shown by the PSI reduced.In other embodiments, the PSI reduced is the observed PSI relative to the engineered immune cell group derived from a non-healthy donor (e.g., a subject suffering from a disease (such as cancer)).In some embodiments, the PSI of an engineered immune cell group or its subgroup can be measured.In one embodiment, subgroup is a CD4+ subgroup or a CD8+ subgroup from an engineered immune cell group.In one embodiment, the PSI of a CD4+ subgroup is about 197 to about 549.
[0125] In one embodiment, the PSI of the CD8+ subset is from about 155 to about 383.
[0126] Next generation sequencing technology can also be used to capture and detect secreted cytokines at the single cell level. In short, the cells of the cell group (for example, the donor cells of the donor cell group and / or the engineered cells of the engineered cell group) are contacted with a labeling agent conjugated with a reporter nucleic acid molecule to provide labeled cells (for example, labeled donor cells and / or labeled engineered cells). In one embodiment, the labeling agent can mark (for example, bind) secreted cytokines. The reporter nucleic acid molecule includes a reporter sequence corresponding to the labeling agent (for example, identifying the cell components of the labeling agent and / or the labeling agent specific labeling, such as specific labeling or binding cytokine antibodies). In one embodiment, the labeled cell includes a complex coupled to the surface of the cell. In another embodiment, the complex includes a capture agent, secreted cytokines and a labeling agent. In one embodiment, the capture agent is configured to be combined with both the cell surface proteins and the secreted cytokines of the cell. In a further embodiment, the labeled cell includes (i) a capture agent combined with cell surface proteins and secreted cytokines and (ii) a labeling agent combined with secreted cytokines. In another embodiment, the cell is contacted with a capture agent prior to contact with a labeling agent, and optionally the cell is contacted with an activator (e.g., an immune cell activator) prior to contact with the capture agent and / or labeling agent. Additional details of the methods and compositions are provided in McDermott et al. WO / 2021 / 072314, which is incorporated herein by reference in its entirety.
[0127] The cell populations described herein (e.g., donor cell populations and / or engineered cell populations) can be analyzed for secretion of various cytokines, including, but not limited to, one or more of granzyme B, IFN-γ, MIP-1α, perforin, TNF-α, TNF-β, GM-CSF, IL-2, IL-5, IL-7, IL-8, IL-9, IL-12, IL-5, IL-21, CCL11, IP-10, MIP-1β, RANTES, IL-2, IL-10, IL-13, IL-22, TGF-β1, sCD137, sCD40L, IL-1β, IL-6, IL-17A, IL-17F, MCP-1, MCP-4, and any combination thereof.
[0128] Determination of in vitro function of CAR T cells
[0129] In this additional aspect, the present disclosure provides a method for analyzing and / or determining the in vitro function of engineered cells of donor cells derived from a donor cell population (including one or more of efficacy (i.e., cytotoxicity), cell fitness, and / or multifunctionality (i.e., cytokine secretion analysis)). In some embodiments, the donor cell is an immune cell. In other embodiments, the engineered cell is an engineered immune cell, such as a CAR T cell. Currently, there are different methods for evaluating the in vitro function of CAR T products. When exposed / bound to target cells, CAR T cells partially exert cytotoxicity by secreting one or more effector cytokines. Effective cytokine induction can be used as an indication of the efficacy or multifunctionality of CAR T cells. The secreted cytokines can be measured by immunoassays (such as ELISA). The cytokine induction of CAR T cells can also be assessed by intracellular staining after fixation of the cells.
[0130] As used herein, efficacy can refer to the ability of one or more immune cells (such as CAR T cells derived from donor cells of a donor cell population) to kill target cells (such as antigen-positive tumor cells).
[0131] As used herein, multifunctionality can refer to the ability of one or more immune cells (such as CAR T cells derived from donor cells of a donor cell population) to secrete more than one effector cytokine or molecule when activated by a target or antigen. In some embodiments, multifunctional CAR T cells secrete two or more effector cytokines, or three or more effector cytokines when activated by a target or antigen.
[0132] The present disclosure provides data demonstrating the correlation between the cell surface expression (e.g., donor cell surface expression and / or engineered cell surface expression) of certain biomarkers and the in vitro function of engineered cells derived from such donor cells. As described herein, markers include negatively correlated markers HLA-DR, TIGIT, CD16 and CD56 and positively correlated markers CD27, CCR7 and CD45RA. HLA-DR is generally considered to be an activation marker, and Saraiva et al. reported that its expression in T cells is positively correlated with the chemotherapy response of breast cancer patients (HLA-DR in Cytotoxic TLymphocytes Predicts Breast Cancer Patients Response to NeoadjuvantChemotherapy. Front Immunol. 2018 Nov 13; 9: 2605. Doi: 10.3389 / fimmu.2018.02605).
[0133] In one aspect, the present disclosure provides a method for detecting the surface expression level of (i) negatively correlated biomarkers (e.g., HLA-DR, TIGIT, CD16, CD56, and any combination thereof) and / or (ii) positively correlated biomarkers (e.g., CD27, CCR7, CD45RA, and any combination thereof) in a cell population as described herein (e.g., see Tables 1-10). In one embodiment, the surface expression level of (i) negatively correlated biomarkers and / or the surface expression level of (ii) positively correlated biomarkers can be used as a representative or indicator of the in vitro function of a cell population. The cell population can be a donor cell population (before any genetic modification) or an engineered cell population, such as a genetically modified cell population derived from a donor cell population, such as a CAR T cell population.
[0134] In one embodiment, the detection step is performed after the cell group is exposed to the activator. The in vitro manipulation of the immune cell group, such as selection, cultivation and expansion, generally includes the use of reagents that activate or stimulate T cells. This activation or stimulation is an important part of the selection and expansion of single cell cloning process. In another aspect, the present disclosure provides an in vitro method for manipulating a donor cell group, the method comprising contacting the donor cells of the donor cell group and / or the engineered cells (e.g., engineered immune cells (such as CAR T cells)) of the donor cells of the donor cell group with one or more activators. Suitable activators include but are not limited to CD3 activators and / or CD28 activators. In one embodiment, the activator includes one or more reagents coupled to a support (such as beads or a matrix, such as a polymer matrix). In another embodiment, the CD3 activator comprises an anti-CD3 antibody and / or the CD28 activator comprises an anti-CD28 antibody. In another embodiment, the activator comprises an IL2R (including IL2Rα, IL2Rβ and IL2Rγ) ligand, such as IL-2 or IL-2 mimetics.
[0135] In another aspect of the disclosure, a population of cells can be contacted or exposed to an activating agent at one or more time points during the process of preparing engineered cells from donor cells, as described herein. Figure 5 Depicted is an exemplary workflow for preparing engineered immune cells from donor cells from a donor cell population as described herein.
[0136] In another embodiment, the detection step can be performed after the engineered immune cell with specificity for the target molecule is contacted with the target molecule or exposed to the target molecule.For example, the CAR T cell expressing a CAR specific for the antigen can be exposed to the antigen or the target cell expressing the antigen.The antigen stimulation (or antigen activation) of CAR T cells can be achieved by, for example, binding to the antigen, binding to the target cell (for example, a target tumor cell expressing an antigen) or by co-culturing with the target cell (for example, a target tumor cell expressing an antigen).In some embodiments, one or more surface biomarkers (positive or negative correlation) of CAR T cells as described herein are measured from about 4 hours to about 10 hours after antigen activation.In other embodiments, one or more surface biomarkers of CAR T cells are measured at about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours or about 10 hours after antigen activation.In some embodiments, one or more surface biomarkers of CAR T cells are measured at about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours or about 10 hours after co-culturing with target cells. In some embodiments, one or more surface biomarkers of the CAR T cell are measured about 6 hours after co-culture with the target cell. In some embodiments, the CAR T cell is an autologous CAR T cell. In some embodiments, the CAR T cell is an allogeneic CAR T cell.
[0137] In some embodiments, the CAR T cell is an autologous CAR T cell. In some embodiments, the CAR T cell is an allogeneic CAR T cell. In some embodiments, the CAR T cell is a TCR-allogeneic CAR T cell. In contrast to TCR+CART cells, in the absence of a functional TCR, the activation of engineered T cells depends on the interaction of CAR with the antigen.
[0138] The present disclosure also provides an overall process for screening, characterizing and analyzing a cell population (such as donor cells from a donor cell population and / or an engineered cell population derived from such donor cells, such as CAR T cells). Therefore, in one aspect, the present disclosure provides a method for analyzing a population of donor cells (such as donor immune cells) or engineered donor cells (such as engineered donor immune cells, such as allogeneic CAR T cells), the method comprising the steps of measuring or determining the percentage or amount of T cells expressing one or more biomarkers in the cell population, and determining the in vitro function of the cell population.
[0139] In some embodiments, the method further comprises a step of measuring the percentage or number of CAR+T cells. In some embodiments, the percentage or number of CAR+T cells can be determined by using a reagent (e.g., an anti-idiotypic antibody or antigen). The antigen can be soluble or fixed on a solid surface. The reagent can be directly labeled for detection, or combined with a secondary labeling reagent for detection. In some embodiments, the method further comprises a step of measuring or detecting CD52+ cells. In some embodiments, CAR T cells are prepared in a GMP preparation process. In some embodiments, the engineered immune cell population is a TCR- allogeneic CAR T cell prepared in a GMP preparation process. In some embodiments, the engineered immune cell population is a GMP allogeneic CAR T bulk drug or medicine.
[0140] In certain embodiments, the CAR T cells are specific for EGFRvIII, WT-1, CD20, CD23, CD30, CD38, CD33, CD133, MHC-WT1, TSPAN10, MHC-PRAME, Liv1, ADAM10, CHRNA2, LeY, NKGD2D, CS1, CD44v6, ROR1, Claudin-18.2, Muc17, FAPα, Ly6G6D, c6orf23, G6D, MEGT1, NG25, CD19, BCMA, FLT3, CD70, DLL3, CD52, or CD34. In certain embodiments, CAR T cells are EGFRvIII CAR T cells, CD19 CAR T cells, CD20 CAR T cells, CD33 CAR T cells, ROR1 CAR T cells, CD70 CART cells, FLT3 CAR T cells, BCMA CAR T cells or DLL3 CAR T cells. In certain embodiments, CAR T cells are BCMA CAR T cells. In certain embodiments, BCMA CAR T cells include BCMA CARs containing the sequences shown in SEQ ID NO: 1 or SEQ ID NO: 2.
[0141] EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMNWVRQAPGKGLEWVSAISDSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYWPMDIWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLMYDASIRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSWPLTFGQGTKVEIKGSGGGGSCPYSNPSLCSGGGGSCPYSNPSLCSGGGGSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR(SEQ ID NO:1)
[0142] EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYPMSWVRQAPGKGLEWVSAIGGGSGGSLPYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYWPMDIWGQGTLVTVSSGGGGSGGGGS GGGGSEIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLMYDASIRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYQSWPLTFGQGTKVEIKGSGGGGSCPYSNP SLCSGGGSCPYSNPSLCSGGGGSTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRF PEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR(SEQ ID NO:2)
[0143] 1. Immune cells
[0144] Donor cells from a donor cell population or engineered cells derived from donor cells suitable for use in the methods and / or reagents described herein include immune cells.
[0145] Before in vitro manipulation or genetic modification (e.g., as described herein), donor cells (e.g., immune cells) for the methods described herein can be obtained from a subject. Donor cells can be obtained from multiple non-limiting sources, including peripheral blood mononuclear cells, bone marrow, lymph node tissue, umbilical cord blood, thymus tissue, stem cells or iPSC-derived immune cells, tissues from infection sites, ascites, pleural effusions, spleen tissue and tumors. In some embodiments, any number of T cell lines available and known to those skilled in the art can be used. In some embodiments, donor cells can be derived from healthy donors, from patients diagnosed with cancer or from patients diagnosed with infection. In some embodiments, donor cells can be a part of a mixed cell population presenting different phenotypic characteristics.
[0146] In some embodiments, the immune cells are autologous immune cells obtained from the subject who will ultimately receive the engineered immune cells. In some embodiments, the immune cells are allogeneic immune cells obtained from a donor who is a different individual than the subject who will receive the engineered immune cells.
[0147] In some embodiments, the immune cells include T cells. T cells can be obtained from a variety of sources, including peripheral blood mononuclear cells (PBMC), bone marrow, lymph node tissue, cord blood, thymus tissue, stem cells or iPSC-derived T cells, tissue from the site of infection, ascites, pleural effusion, spleen tissue and tumors. In certain embodiments, any number of techniques known to the skilled person can be used, such as FICOLL TM Isolate and obtain T cells from a volume of blood collected from a subject.
[0148] Donor cells can be obtained from the circulating blood of an individual by apheresis. The apheresis product typically contains lymphocytes, including T cells, monocytes, granulocytes, B cells, other nucleated leukocytes, red blood cells, and platelets. In certain embodiments, the cells collected by apheresis can be washed to remove plasma components and placed in an appropriate buffer or culture medium for subsequent processing.
[0149] Using methods as described herein, donor PBMC can be directly used for the genetic modification of immune cells (such as CAR or TCR). In certain embodiments, after separating PBMC, T lymphocytes can be further separated, and cytotoxic and helper T lymphocytes can be sorted into primary, memory and effector T cell subsets before or after genetic modification and / or amplification.
[0150] In certain embodiments, for example, using PERCOLL TMGradient centrifugation, by lysing red blood cells and removing monocytes, separates T cells from PBMC. T cells, such as CCR7+, CD95+, CD122, CD27+, CD69+, CD127+, CD28+, CD3+, CD4+, CD8+, CD25+, CD62L+, CD45RA+ and CD45RO+T cells can be further separated by positive or negative selection techniques known in the art. For example, the enrichment of T cell colonies by negative selection can be realized by a combination of antibodies for surface markers unique to cells for negative selection. One of the methods used herein is to sort cells and / or select by negative magnetic immunoadhesion or flow cytometry, which uses a monoclonal antibody mixture for cell surface markers present on cells for negative selection. For example, in order to enrich for CD4+ cells by negative selection, a monoclonal antibody mixture generally includes antibodies for CD14, CD20, CD11b, CD16, HLA-DR and CD8. Flow cytometry and cell sorting can also be used to isolate cell populations of interest for use in the present disclosure.
[0151] In one embodiment, in order to eliminate unwanted cells that express one or more cell surface biomarkers (e.g., HLA-DR, TIGIT, CD16, CD56, and any combination thereof), one or more antibodies against such one or more cell surface biomarkers present on the unwanted cells can be used to enrich cells that do not express the cell surface biomarkers.
[0152] In some embodiments, the donor cell (eg, immune cell, such as T cell) population is enriched for CD4+ cells.
[0153] In some embodiments, the donor cell (eg, immune cell, such as T cell) population is enriched for CD8+ cells.
[0154] In some embodiments, CD8+ cells are further sorted into primary, central memory, and effector cells by identifying cell surface antigens associated with each of these cell types. In some embodiments, the expression of phenotypic markers of primary T cells includes CD45RA+, CD95-, IL2Rβ-, CCR7+, and CD62L+. In some embodiments, the expression of phenotypic markers of stem cell memory T cells includes CD45RA+, CD95+, IL2Rβ+, CCR7+, and CD62L+. In some embodiments, the expression of phenotypic markers of central memory T cells includes CD45RO+, CD95+, IL2Rβ+, CCR7+, and CD62L+. In some embodiments, the expression of phenotypic markers of effector memory T cells includes CD45RO+, CD95+, IL2Rβ+, CCR7-, and CD62L-. In some embodiments, the expression of phenotypic markers of T effector cells includes CD45RA+, CD95+, IL2Rβ+, CCR7-, and CD62L-. Thus, CD4+ and / or CD8+ T helper cells can be sorted into naive, stem cell memory, central memory, effector memory, and T effector cells by identifying cell populations that have cell surface antigens.
[0155] It should be understood that donor PBMCs may further comprise other cytotoxic lymphocytes, such as NK cells or NKT cells. Expression vectors carrying coding sequences of chimeric receptors as disclosed herein may be introduced into populations of human donor T cells, NK cells or NKT cells. Standard procedures are used to cryopreserve CAR-expressing T cells for storage and / or preparation for human individuals. In one embodiment, in vitro transduction, culture and / or expansion of T cells are performed in the absence of non-human animal-derived products, such as fetal bovine serum (fetal calf serum / fetal bovine serum). In various embodiments, cryopreservation medium may include, for example CS2, CS5 or CS10 or other medium containing DMSO, or medium without DMSO.
[0156] 2. Engineered immune cells
[0157] Provided herein are engineered immune cells (e.g., CAR-T cells) derived from donor cells as described herein expressing CAR disclosed herein. In one embodiment, engineered immune cells (i) are derived from donor cells of a donor cell population with a biomarker spectrum as described herein, and (ii) are characterized by improved in vitro function compared to engineered immune cells derived from donor cells lacking a biomarker spectrum.
[0158] In some embodiments, the engineered immune cells include a CAR population, each CAR including an extracellular antigen binding domain. In some embodiments, the engineered immune cells include a CAR population, each CAR including different extracellular antigen binding domains. In some embodiments, the immune cells include a CAR population, each CAR including the same extracellular antigen binding domain.
[0159] The engineered immune cells can be allogeneic or autologous.
[0160] In some embodiments, the engineered immune cell is a T cell (e.g., inflammatory T lymphocytes, cytotoxic T lymphocytes, regulatory T lymphocytes, helper T lymphocytes, tumor infiltrating lymphocytes (TIL)), NK cells, NK-T cells, TCR-expressing cells, dendritic cells, killer dendritic cells, mast cells, or B cells.
[0161] In one embodiment, the engineered immune cells can be derived from donor cells having a biomarker profile as described herein. In some embodiments, the engineered immune cells can be derived from a group consisting of CD4+T lymphocytes and CD8+T lymphocytes. In some exemplary embodiments, the engineered immune cells are T cells. In some exemplary embodiments, the engineered immune cells are αβT cells. In some exemplary embodiments, the engineered immune cells are γδT cells. In some exemplary embodiments, the engineered immune cells are macrophages.
[0162] In some embodiments, the engineered immune cells can be derived from, for example but not limited to, stem cells. Stem cells can be adult stem cells, non-human embryonic stem cells, more specifically non-human stem cells, umbilical cord blood stem cells, progenitor cells, bone marrow stem cells, induced pluripotent stem cells (iPSCs), totipotent stem cells, or hematopoietic stem cells. Stem cells can be CD34+ or CD34-.
[0163] In some embodiments, donor cells are obtained from peripheral blood or prepared therefrom. In some embodiments, donor cells are obtained from peripheral blood mononuclear cells (PBMC) or prepared therefrom. In some embodiments, donor cells are obtained from bone marrow or prepared therefrom. In some embodiments, donor cells are obtained from umbilical cord blood or prepared therefrom. In some embodiments, donor cells are human cells. In some embodiments, a method selected from the group consisting of the following is used to transfect or transduce by a nucleic acid vector: electroporation, sonoporation, biolistics (e.g., gene gun), transfection, lipofection, polymer transfection, nanoparticles, viral transduction or viral transfection (e.g., retrovirus, slow virus, AAV) or polymer complex (polyplex). In some embodiments, donor cells are T cells that have been reprogrammed from non-T cells. In some embodiments, donor cells are T cells that have been reprogrammed from T cells.
[0164] Binding agents (including antibodies and their fragments)
[0165] In embodiments, the disclosed methods for identification or detection include the use of an antibody or an antigen binding agent (e.g., comprising an antigen binding domain or comprising an antibody or fragment thereof). As discussed below, in various embodiments, the engineered immune cells derived from donor cells of a donor cell population may also comprise a binding agent.
[0166] As used herein, the term "antibody" refers to a polypeptide comprising canonical immunoglobulin sequence elements sufficient to confer specific binding to a specific target antigen. As known in the art, a complete antibody produced in nature is a tetrameric reagent of approximately 150 kD, comprising two identical heavy chain polypeptides (each about 50 kD) and two identical light chain polypeptides (each about 25 kD), which are associated with each other into a structure generally referred to as a "Y-shape". Each heavy chain comprises at least four domains (each about 110 amino acids in length) - these four domains are amino-terminal variable (VH) domains (located at the end of the Y structure), followed by three constant domains: CHI, CH2, and carboxyl-terminal CH3 (located at the base of the stem of the Y). The short region is called a "switch" that connects the heavy chain variable region to the constant region. The "hinge" connects the CH2 and CH3 domains to the rest of the antibody. Two disulfide bonds in the hinge region connect the two heavy chain polypeptides in the complete antibody to each other. Each light chain is composed of two domains - the two domains are an amino-terminal variable (VL) domain followed by a carboxyl-terminal constant (CL) domain. Those skilled in the art are very familiar with antibody structure and sequence elements, recognize the "variable" and "constant" regions in the provided sequences, and understand that there can be some flexibility in defining the "borders" between these domains, so that different presentations of the same antibody chain sequence can, for example, mean that such borders at a certain position are offset by one or a few residues relative to different presentations of the same antibody chain sequence.
[0167] The complete antibody tetramer contains two heavy chain-light chain dimers, in which the heavy chain and the light chain are connected to each other by a single disulfide bond; the other two disulfide bonds connect the heavy chain hinge regions to each other, thereby connecting the dimers to each other and forming a tetramer. Naturally produced antibodies are also glycosylated, usually on the CH2 domain. Each domain in a natural antibody has a structure characterized by an "immunoglobulin fold", which is formed by stacking two β folds (e.g., 3, 4 or 5 chain folds) in a compressed antiparallel β barrel. Each variable domain contains three hypervariable loops called "complement determining regions" (CDR1, CDR2 and CDR3) and four slightly unchanged "framework" regions (FR1, FR2, FR3 and FR4). When the natural antibody is folded, the FR region forms a β fold that provides a structural framework for the domain, and the CDR loop regions of the heavy and light chains are gathered together in three-dimensional space, thereby generating a single hypervariable antigen binding site located at the end of the Y structure. The Fc region of a naturally occurring antibody binds to elements of the complement system and also to receptors on effector cells (including, for example, effector cells that mediate cytotoxicity). As is known in the art, the affinity and / or other binding properties of the Fc region for Fc receptors can be modulated by glycosylation or other modifications. In some embodiments, antibodies produced and / or employed in accordance with the present invention comprise a glycosylated Fc domain, including Fc domains having modified or engineered such glycosylation.
[0168] For the purposes of this disclosure, in certain embodiments, any polypeptide or polypeptide complex comprising sufficient immunoglobulin domain sequences present in natural antibodies may be referred to and / or used as an "antibody", whether such polypeptide is produced naturally (e.g., by an organism reacting with an antigen) or produced by recombinant engineered, chemically synthesized, or other artificial systems or methods. In some embodiments, the antibodies are polyclonal; in some embodiments, the antibodies are monoclonal. In some embodiments, the antibodies have constant region sequences that are characteristic of mouse, rabbit, primate, or human antibodies. In some embodiments, antibody sequence elements are humanized, primatized, chimeric, etc., as known in the art.
[0169] In addition, the term "antibody" as used herein may refer to any of the constructs or forms known or developed in the art for utilizing antibody structural and functional characteristics in alternative presentation. For example, in some embodiments, the form of the antibody employed in the methods of the present disclosure is selected from, but not limited to: a complete IgA, IgG, IgE, or IgM antibody; a bispecific or multispecific antibody (e.g., , etc.); antibody fragments, such as Fab fragments, Fab fragments, F(ab)2 fragments, Fd fragments and isolated CDRs or collections thereof; single chain variable fragments (scFV); polypeptide-Fc fusions; single domain antibodies (e.g., shark single domain antibodies, such as IgNAR or fragments thereof); camelid antibodies (also referred to herein as nanobodies or VHH); shark antibodies, masked antibodies (e.g., ); Small modular immunopharmaceuticals (SMIPs) TM ); single-chain or tandem bivalent antibodies VHH; microantibodies; Ankyrin repeat protein or DART;TCR-like antibody; microprotein; and In some embodiments, the antibody may lack covalent modifications (e.g., attachment of polysaccharides) that are present in nature. In some embodiments, the antibody may contain covalent modifications (e.g., attachment of polysaccharides), payloads (e.g., detectable moieties, therapeutic moieties, catalytic moieties, etc.), or other side groups (e.g., polyethylene glycol, etc.).
[0170] As used herein, the term "antibody reagent" generally refers to a reagent that specifically binds to a specific antigen. In some embodiments, the term encompasses any polypeptide or polypeptide complex comprising an immunoglobulin structural element sufficient to confer specific binding. Exemplary antibody reagents include, but are not limited to, monoclonal antibodies or polyclonal antibodies. In some embodiments, the antibody reagent may include one or more constant region sequences that have the characteristics of mouse, rabbit, primate or human antibodies. In some embodiments, the antibody reagent may include one or more sequence elements that are humanized, primatized, chimeric, etc., as known in the art. In multiple embodiments, the term "antibody reagent" is used to refer to one or more of the constructs or forms known or developed in the art for utilizing antibody structure and functional characteristics in alternative presentation. For example, the form of the antibody reagent used according to the present invention is selected from, but not limited to: complete IgA, IgG, IgE or IgM antibodies; bispecific or multispecific antibodies (e.g., etc.); antibody fragments, such as Fab fragments, Fab' fragments, F(ab')2 fragments, Fd fragments and isolated CDRs or collections thereof; single-chain Fv; polypeptide-Fc fusions; single-domain antibodies (e.g., shark single-domain antibodies, such as IgNAR or fragments thereof); camel antibodies; masked antibodies (e.g., ); Small modular immunopharmaceuticals (SMIPs) TM); single-chain or tandem bivalent antibodies VHH; microantibodies; Ankyrin repeat protein or DART;TCR-like antibody; microprotein; and
[0171] The antibody or antibody reagent for carrying out the method of the present disclosure can be single-stranded or double-stranded. In some embodiments, the antibody or antigen-binding molecule is single-stranded. In certain embodiments, the antigen-binding molecule is selected from the group consisting of the following: scFv, Fab, Fab', Fv, F(ab')2, dAb and any combination thereof.
[0172] Antibodies and antibody reagents include antibody fragments. Antibody fragments include a portion of a complete antibody, such as the antigen binding or variable region of a complete antibody. Antibody fragments include, but are not limited to, Fab, Fab', Fab'-SH, F(ab')2, Fv, bivalent antibodies, linear antibodies, multispecific antibodies formed by antibody fragment antibodies and scFv fragments and other fragments. Antibodies also include, but are not limited to, polyclonal, monoclonal, chimeric dAb (domain antibodies), single chain, Fab, Fa, F(ab')2 fragments and scFv. Antibodies can be complete antibodies, or immunoglobulins, or antibody fragments. Antibody fragments can be prepared by a variety of techniques, including but not limited to proteolytic digestion of complete antibodies and production by recombinant host cells (e.g., Escherichia coli (E. coli), Chinese hamster ovary (CHO) cells or phages), as known in the art.
[0173] In some embodiments, the antibody or antibody reagent may be a chimeric antibody (see, e.g., U.S. Pat. No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984)). A chimeric antibody may be an antibody in which a portion of the heavy chain and / or light chain is derived from a particular source or species, while the remainder of the heavy chain and / or light chain is derived from a different source or species. In one example, a chimeric antibody may include a non-human variable region (e.g., a variable region derived from a mouse, rat, hamster, rabbit, or non-human primate (such as a monkey)) and a human constant region. In another example, a chimeric antibody may be a "class-switched" antibody in which the class or subclass has been changed from a parent antibody. A chimeric antibody comprises an antigen-binding fragment thereof.
[0174] In some embodiments, the chimeric antibody can be a humanized antibody (see, e.g., Almagro and Fransson, Front. Biosci., 13:1619-1633 (2008); Riechmann et al., Nature, 332:323-329 (1988); Queen et al., Proc. Natl Acad. Sci. USA, 86:10029-10033 (1989); U.S. Pat. Nos. 5,821,337, 7,527,791, and 8,537,792 (1991). Nos. 6,982,321 and 7,087,409; Kashmiri et al., Methods 36:25-34 (2005); Padlan, Mol. Immunol, 28:489-498 (1991); Dall'Acqua et al., Methods 36:43-60 (2005); Osbourn et al., Methods 36:61-68 (2005); and Klimka et al., Br. J. Cancer 83:252-260 (2000). Humanized antibodies are chimeric antibodies that include amino acid residues from non-human hypervariable regions and amino acid residues from human FRs. In certain embodiments, a humanized antibody will include substantially all of at least one, typically two variable domains, wherein all or substantially all of the hypervariable regions (e.g., CDRs) correspond to those of a non-human antibody, and all or substantially all of the framework regions (FRs) correspond to those of a human antibody. A humanized antibody optionally may include at least a portion of an antibody constant region derived from a human antibody.
[0175] In some embodiments, the antibodies or antibody reagents provided herein are human antibodies. Human antibodies can be produced using various techniques known in the art (see, for example, van Dijk and van de Winkel, Curr. Opin. Pharmacol., 5: 368-74 (2001); and Lonberg, Curr. Opin. Immunol, 20: 450-459 (2008)). Human antibodies can be antibodies whose amino acid sequences correspond to those produced by humans or human cells or derived from antibodies of non-human origin using human antibody pedigrees or other human antibody encoding sequences. This definition of human antibodies explicitly excludes humanized antibodies including non-human antigen binding residues. Human antibodies can be prepared using methods well known in the art.
[0176] Chimeric Antigen Receptor
[0177] As used herein, a chimeric antigen receptor (CAR) is a protein that specifically recognizes a target antigen (e.g., a target antigen on a cancer cell). When bound to a target antigen, CAR can activate immune cells to attack and destroy cells carrying the antigen (e.g., cancer cells). CAR can also have co-stimulatory or signaling domains to increase its effectiveness. See Krause et al., Journal of Experimental Medicine (J. Exp. Med.), Vol. 188, No. 4, 1998 (619–626); Finney et al., Journal of Immunology (Journal of Immunology) Immunology, 1998, 161:2791–2797; Song et al., Blood, 119:696-706 (2012); Kalos et al., Sci. Transl. Med., 3:95 (2011); Porter et al., N. Engl. J. Med., 365:725-33 (2011); and Gross et al., Annu. Rev. Pharmacol. Toxicol., 56:59-83 (2016); U.S. Pat. Nos. 7,741,465 and 6,319,494.
[0178] The chimeric antigen receptor described herein comprises an extracellular domain, a transmembrane domain and an intracellular domain, wherein the extracellular domain comprises an antigen binding domain that specifically binds to a target.
[0179] In some embodiments, the antigen-specific CAR further comprises a safety switch and / or one or more monoclonal antibody-specific epitopes.
[0180] i. Antigen binding domain
[0181] As discussed above, the CAR described herein includes an antigen binding domain. As used herein, "antigen binding domain" means any polypeptide that binds to a specified target antigen. In some embodiments, the antigen binding domain binds to an antigen on a tumor cell. In some embodiments, the antigen binding domain binds to an antigen on a cell involved in a hyperproliferative disease.
[0182] In some embodiments, the antigen binding domain comprises a variable heavy chain, a variable light chain and / or one or more CDRs as described herein. In some embodiments, the antigen binding domain is a single chain variable fragment (scFv) comprising a light chain CDR (CDR1, CDR2 and CDR3) and a heavy chain CDR (CDR1, CDR2 and CDR3).
[0183] An antigen binding domain is said to be "selective" when it binds one target more tightly or with higher affinity than it binds a second target.
[0184] The antigen binding domain of CAR selectively targets cancer antigens. In some embodiments, the cancer antigen is selected from EGFRvIII, WT-1, CD20, CD23, CD30, CD38, CD33, CD133, MHC-WT1, TSPAN10, MHC-PRAME, Liv1, ADAM10, CHRNA2, LeY, NKGD2D, CS1, CD44v6, ROR1, Claudin-18.2, Muc17, FAPα, Ly6G6D, c6orf23, G6D, MEGT1, NG25, CD19, BCMA, FLT3, CD70, DLL3, CD52 or CD34. In some embodiments, the CAR comprises an antigen binding domain that targets EGFRvIII, WT-1, CD20, CD23, CD30, CD38, CD33, CD133, MHC-WT1, TSPAN10, MHC-PRAME, Liv1, ADAM10, CHRNA2, LeY, NKGD2D, CS1, CD44v6, ROR1, Claudin-18.2, Muc17, FAPα, Ly6G6D, c6orf23, G6D, MEGT1, NG25, CD19, BCMA, FLT3, CD70, DLL3, CD52, or CD34.
[0185] In some embodiments, the cancer antigen is selected from the group consisting of carbonic anhydrase IX (CAIX), carcinoembryonic antigen (CEA), CDS, CD7, CDIO, CD19, CD20, CD22, CD30, CD33, CD34, CD38, CD41, CD44, CD49f, CD56, CD74, CD123, CD133, CD138, antigens of cytomegalovirus (CMV) infected cells (e.g., cell surface antigens), epithelial glycoprotein (EGP 2), epithelial glycoprotein-40 (EGP-40), epithelial cell adhesion molecule (EpCAM), receptor tyrosine protein kinase erb-B2,3,4, folate binding protein (FBP), fetal acetylcholine receptor (AChR), folate receptor, ganglioside G2 (GD2), ganglioside G3 (GD3), human epidermal growth factor receptor 2 (HER-2), human telomerase reverse transcriptase (hTERT), interleukin-13 receptor subunit alpha-2 (IL-13Ra2), kappa-light chain, kinase insert domain receptor (KDR), Lewis A (CA19.9), LI cell adhesion molecule (LICAM), melanoma antigen family A, 1 (MAGE-AI), mucin 16 (Muc-16), mucin 1 (Muc-1), mesothelin (MSLN), NKG2D ligand, cancer-testis antigen NY-ESO-1, carcinoembryonic antigen (h5T4), prostate stem cell antigen (PSCA), prostate specific membrane antigen (PSMA), tumor-associated glycoprotein 72 (TAG-72), vascular endothelial growth factor R2 (VEGF-R2) and Wilms tumor protein (WT-1).
[0186] Variants of antigen binding domains (e.g., variants of CDRs, VH and / or VL) are also within the scope of the present disclosure, e.g., variable light chains and / or variable heavy chains, each of which has at least 70%-80%, 80%-85%, 85%-90%, 90%-95%, 95%-97%, 97%-99% or greater than 99% identity to the amino acid sequence of the antigen binding domain sequence. In some cases, such molecules comprise at least one heavy chain and one light chain, while in other cases, the variant forms contain two variable light chains and two variable heavy chains (or sub-portions thereof). Technicians will be able to use well-known techniques to determine suitable variants of antigen binding domains as shown herein. In certain embodiments, those skilled in the art can identify suitable regions of the molecule by targeting regions that are considered to be unimportant for activity, which regions can be changed without destroying activity.
[0187] In certain specific embodiments, the polypeptide structure of the antigen binding domain is based on antibodies, including but not limited to monoclonal antibodies, bispecific antibodies, miniantibodies, domain antibodies, synthetic antibodies (sometimes referred to herein as "antibody mimetics"), chimeric antibodies, humanized antibodies, human antibodies, antibody fusions (sometimes referred to herein as "antibody conjugates"), and fragments thereof, respectively. In some embodiments, the antigen binding domain comprises or consists of an avimer.
[0188] In some embodiments, the antigen binding domain is a scFv.
[0189] In some embodiments, the antigen-selective CAR includes a leader sequence or a signal peptide.
[0190] In other embodiments, the present disclosure relates to isolated polynucleotides encoding any one of the antigen binding domains described herein. In some embodiments, the present disclosure relates to isolated polynucleotides encoding CAR. Also provided herein are vectors including polynucleotides and methods for preparing them.
[0191] In other embodiments, the present disclosure relates to isolated polynucleotides encoding any one of the antigen binding domains described herein. In some embodiments, the present disclosure relates to isolated polynucleotides encoding CAR. Also provided herein are vectors including polynucleotides and methods for preparing them.
[0192] In some embodiments, CAR immune cells (e.g., CAR-T cells) can form a component of an engineered immune cell population (derived from a donor cell population as described herein) generated by implementing the method of the present disclosure, and the CAR immune cell comprises a polynucleotide encoding a safety switch polypeptide (e.g., RQR8). See, for example, WO2013153391A, which is hereby incorporated by reference in its entirety. In a CAR immune cell (e.g., CAR-T cell) comprising a polynucleotide, a safety switch polypeptide can be expressed on the surface of a CAR immune cell (e.g., CAR-T cell).
[0193] ii. Hinge domain
[0194] The extracellular domain of the CAR disclosed herein may include a "hinge" domain (or hinge region). The term generally refers to any such polypeptide having the function of connecting the transmembrane domain in CAR to the extracellular antigen-binding domain in CAR. Specifically, the hinge domain can be used to provide greater flexibility and accessibility for the extracellular antigen-binding domain.
[0195] The hinge domain may include up to 300 amino acids - in some embodiments 10 to 100 amino acids or in some embodiments, 25 to 50 amino acids. The hinge domain may be derived from all or part of a naturally occurring molecule, such as all or part of the extracellular region of CD8, CD4, CD28, 4-1BB or IgG (especially, the hinge region of IgG; it should be understood that the hinge region may contain members of the immunoglobulin family, such as some or all of IgG1, IgG2, IgG3, IgG4, IgA, IgD, IgE, IgM or their fragments), or from all or part of the constant region of the heavy chain of an antibody. Alternatively, the hinge domain may be a synthetic sequence corresponding to a naturally occurring hinge sequence, or may be a fully synthetic hinge sequence. In some embodiments, the hinge domain is a portion of a human CD8 α chain (e.g., NP_001139345.1). In other embodiments, the hinge and transmembrane domain include a portion of a human CD8 α chain. In some embodiments, the hinge domain of the CAR described herein includes a subsequence of CD8α, IgG1, IgG4, PD-1 or FcγRIIIα, in particular a hinge region of any one of CD8α, IgG1, IgG4, PD-1 or FcγRIIIα. In some embodiments, the hinge domain includes a human CD8α hinge, a human IgG1 hinge, a human IgG4, a human PD-1 or a human FcγRIIIα hinge. In some embodiments, the CAR disclosed herein includes scFv, a CD8α human hinge and a transmembrane domain, a CD3ζ signaling domain and a 4-1BB signaling domain.
[0196] iii. Transmembrane domain
[0197] The CAR of the present disclosure is designed to have a transmembrane domain fused to the extracellular domain of CAR. It can be similarly fused to the intracellular domain of CAR. In some cases, the transmembrane domain can be selected or modified by amino acid substitution to avoid such domains from binding to the transmembrane domain of the same or different surface membrane proteins, thereby minimizing the interaction with other members of the receptor complex. In some embodiments, a short linker can form a bond between any one or some of the extracellular, transmembrane and intracellular domains of CAR.
[0198] Suitable transmembrane domains of the CARs disclosed herein have the ability to: (a) express on the surface of immune cells, such as, but not limited to, lymphocytes, such as T helper cells (T h ) cells, cytotoxic T (T c ) cells, T regulatory (T reg) cells or natural killer (NK) cells, and / or (b) interact with the extracellular antigen binding domain and the intracellular signaling domain to direct the cellular response of the immune cell against the target cell.
[0199] The transmembrane domain may be derived from a natural or synthetic source. When the source is natural, the domain may be derived from any membrane-bound or transmembrane protein.
[0200] The transmembrane region particularly used in the present disclosure may be derived from (including, or corresponding to) CD28, OX-40, 4-1BB / CD137, CD2, CD7, CD27, CD30, CD40, programmed death-1 (PD-1), inducible T cell co-stimulatory molecule (ICOS), lymphocyte function-associated antigen-1 (LFA-1, CD1-1a / CD18), CD3γ, CD3δ, CD3ε, CD247, CD276 (B7-H3), LIGHT, (TNFSF14), NKG2C, Igα (CD79a), DAP-10, Fcγ receptor, MHC Class 1 molecules, TNF receptor proteins, immunoglobulins, cytokine receptors, integrins, signaling lymphocyte activation molecules (SLAM proteins), activated NK cell receptors, BTLA, Toll ligand receptors, ICAM-1, B7-H3, CDS, ICAM-1, GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8α, CD8β, IL-2Rβ, IL-2Rγ, IL-7Rα, ITGA4, VLA1, C D49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, C D29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, TNFR2, TRANCE / RANKL, DNAM1(CD226), SLAMF4(CD244, 2B4), CD84, CD96(Tactile), CEACAM1, CRT AM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG / Cbp, CD19a, a ligand that specifically binds to CD83, or any combination thereof.
[0201] As a non-limiting example, the transmembrane region can be derived from a T cell receptor, or a part of a T cell receptor, such as α, β, γ or δ, a polypeptide constituting a CD3 complex, an IL-2 receptor p55 (a chain), p75 (β chain) or a γ chain, a subunit chain of an Fc receptor, especially Fcγ receptor III or CD protein. Alternatively, the transmembrane domain can be synthetic and can mainly include hydrophobic residues, such as leucine and valine. In some embodiments, the transmembrane domain is derived from a human CD8 α chain (e.g., NP_001139345.1).
[0202] In some embodiments, the transmembrane domain in the CAR of the present disclosure is a CD8α transmembrane domain.
[0203] In some embodiments, the transmembrane domain in the CAR of the present disclosure is a CD28 transmembrane domain.
[0204] iv. Intracellular domain
[0205] The intracellular (cytoplasmic) domain of the CAR of the present disclosure can provide at least one activation of the normal effector function of the immune cell including the CAR. For example, the effector function of T cells can refer to cell lysis activity or auxiliary cell activity, including the secretion of cytokines.
[0206] In some embodiments, the activating intracellular signaling domain for use in a CAR may be, for example, but not limited to, cytoplasmic sequences of T cell receptors and co-receptors that act coordinately to initiate signal transduction after antigen receptor binding, as well as any derivatives or variants of these sequences and any synthetic sequences with the same functional capability.
[0207] It is understood that suitable (e.g., activation) intracellular domains include, but are not limited to, signaling domains derived from (or corresponding to) CD28, OX-40, 4-1BB / CD137, CD2, CD7, CD27, CD30, CD40, programmed death-1 (PD-1), inducible T cell co-stimulatory molecule (ICOS), lymphocyte function-associated antigen-1 (LFA-1, CD1-1a / CD18), CD3γ, CD3δ, D3ε, CD247, CD276 (B7-H3), LIGHT, (TNFSF14), NKG2C, Igα (CD79a), DAP-10, Fcγ receptor, MHC Class 1 molecules, TNF receptor proteins, immunoglobulin proteins, cytokine receptors, integrins, signaling lymphocyte activation molecules (SLAM proteins), activated NK cell receptors, BTLA, Toll ligand receptors, ICAM-1, B7-H3, CDS, ICAM-1, GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8α, CD8β, IL-2Rβ, IL-2Rγ, IL-7Rα, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, C D29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, TNFR2, TRANCE / RANKL, DNAM1(CD226), SLAMF4(CD244, 2B4), CD84, CD96(Tactile), CEACAM1, CRT AM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG / Cbp, CD19a, a ligand that specifically binds to CD83, or any combination thereof.
[0208] The intracellular domain of the CAR of the present disclosure may also be incorporated into a costimulatory signaling domain (interchangeably referred to herein as a costimulatory molecule) in addition to the above-mentioned activation domain to increase its effectiveness. The costimulatory domain may provide a signal other than the primary signal provided by the activation molecule as described herein.
[0209] It will be appreciated that suitable costimulatory domains within the scope of the present disclosure may be derived from (or correspond to) for example, CD28, OX40, 4-1BB / CD137, CD2, CD3 (α, β, δ, ε, γ, ζ), CD4, CD5, CD7, CD9, CD16, CD22, CD27, CD30, CD33, CD37, CD40, CD45, CD64, CD80, CD86, CD134, CD137, CD154, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1 (CD11a / CD18), CD247, CD276 (B7-H3), LIGHT (tumor necrosis factor superfamily member 14; TNFSF14), NKG2C, Igα (CD79a), DAP-10, Fcγ receptor, MHC Class I molecules, TNFR, integrin, signaling lymphocyte activation molecules, BTLA, Toll ligand receptor, ICAM-1, B7-H3, CDS, ICAM-1, GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8α, CD8β, IL-2Rβ, IL-2Rγ, IL-7Rα, ITGA4, VLA1, CD49a, ITGA4, IA4, CD4 9D, ITGA6, VLA-6, CD49f, ITGAD, CD1-1d, ITGAE, CD103, ITGAL, CD1-1a, LFA-1, ITGAM, CD1-1b, ITGAX, CD1-1c, ITGB1, CD29, ITG B2, CD18, LFA-1, ITGB7, NKG2D, TNFR2, TRANCE / RANKL, DNAM1(CD226), SLAMF4(CD244, 2B4), CD84, CD96(Tactile), CEACAM1, CRT AM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG / Cbp, CD19a, CD83 ligand, or a fragment or combination thereof. It should be understood that additional costimulatory molecules or fragments thereof not listed above are within the scope of the present disclosure.
[0210] In some embodiments, the intracellular / cytoplasmic domain of CAR can be designed to include the 4-1BB / CD137 domain itself or any other desired intracellular domain combination suitable for the situation of CAR of the present disclosure. The complete native amino acid sequence of 4-1BB / CD137 is described in NCBI reference sequence: NP_001552.2. The complete native 4-1BB / CD137 nucleic acid sequence is described in NCBI reference sequence: NM_001561.5.
[0211] In some embodiments, the intracellular / cytoplasmic domain of the CAR can be designed to include the CD28 domain itself or in combination with any other desired intracellular domain suitable for the context of the CAR of the present disclosure. The complete native amino acid sequence of CD28 is described in NCBI reference sequence: NP_006130.1. The complete native CD28 nucleic acid sequence is described in NCBI reference sequence: NM_006139.1.
[0212] In some embodiments, the intracellular / cytoplasmic domain of the CAR can be designed to include the CD3 zeta domain by itself or in combination with any other desired intracellular domain suitable for the context of the CAR of the present disclosure.
[0213] For example, the intracellular domain of CAR can include a portion of a CD3 ζ chain and a portion of a co-stimulatory signaling molecule. The intracellular signaling sequences within the intracellular signaling portion of the CAR disclosed herein can be connected to each other randomly or in a specified order. In some embodiments, the intracellular domain is designed to include an activation domain of CD3 ζ and a signaling domain of CD28. In some embodiments, the intracellular domain is designed to include an activation domain of CD3 ζ and a signaling domain of 4-1BB.
[0214] In some embodiments, the intracellular signaling domain of CAR of the present disclosure includes the domain of a costimulatory molecule. In some embodiments, the intracellular signaling domain of CAR of the present disclosure includes a portion of a costimulatory molecule selected from the group consisting of a fragment of 4-1BB (GenBank: AAA53133.) and CD28 (NP_006130.1).
[0215] Engineered immune cells containing CAR
[0216] Also provided herein is an engineered immune cell expressing CAR and an engineered immune cell group (e.g., CAR-T cells or CAR+ cells), which is derived from donor cells with a biomarker spectrum detected according to the method described herein. Such engineered immune cells can be cells expressing one or more unwanted biomarkers (e.g., HLA-DR, TIGIT, CD16, CD56, and any combination thereof) and / or endogenous TCRs that have been eliminated.
[0217] In some embodiments, the engineered immune cells include CAR T cells, each CAR T cell includes an extracellular antigen binding domain and one or more required biomarkers (as described herein) and / or endogenous TCR expression is reduced or eliminated. In some embodiments, the engineered immune cell population includes a CAR T cell population, each CART cell includes two or more different extracellular antigen binding domains and endogenous TCR expression is reduced or eliminated. In some embodiments, the immune cells include a CAR population, each CAR T cell includes the same extracellular antigen binding domain and one or more required biomarkers (as described herein) and / or endogenous TCR expression is reduced or eliminated.
[0218] The engineered immune cells can be allogeneic or autologous.
[0219] In some embodiments, the engineered immune cell or engineered immune cell population is a T cell (e.g., inflammatory T lymphocyte cytotoxic T lymphocyte, regulatory T lymphocyte, helper T lymphocyte, tumor infiltrating lymphocyte (TIL)), NK cell, NK-T cell, TCR expressing cell, dendritic cell, killer dendritic cell, mast cell or B cell, and expresses CAR. In some embodiments, T cells can be derived from a group consisting of CD4+T lymphocytes, CD8+T lymphocytes, or a group comprising a combination of CD4+ and CD8+T cells.
[0220] In some embodiments, the engineered immune cells or engineered immune cell populations produced using the disclosed methods can be derived from, for example, but not limited to, stem cells. The stem cells can be adult stem cells, non-human embryonic stem cells, more specifically non-human stem cells, umbilical cord blood stem cells, progenitor cells, bone marrow stem cells, induced pluripotent stem cells, totipotent stem cells, or hematopoietic stem cells.
[0221] In some embodiments, the engineered immune cells or immune cell groups generated using the disclosed method are obtained from peripheral blood or prepared therefrom, wherein the peripheral blood comprises donor cells from a donor cell group with a biomarker spectrum as described herein. In some embodiments, the engineered immune cells are obtained from peripheral blood mononuclear cells (PBMC) or prepared therefrom. In some embodiments, the engineered immune cells are obtained from bone marrow or prepared therefrom. In some embodiments, the engineered immune cells are obtained from umbilical cord blood or prepared therefrom. In some embodiments, the donor cells are human cells. In some embodiments, the donor cells are transfected or transduced by a nucleic acid vector using a method selected from the group consisting of the following: electroporation, sonoporation, biolistics (e.g., gene gun), lipofection, polymer transfection, nanoparticles, viral transfection (e.g., retrovirus, slow virus, AAV) or polymer complex (polyplex).
[0222] In some embodiments, the engineered immune cells expressing antigen-specific CARs on the cell surface membrane include percentages greater than 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% stem cell memory and central memory cells.
[0223] In some embodiments, the engineered immune cells expressing an antigen-specific CAR on the cell surface membrane include percentages of about 10% to about 60%, about 10% to about 50%, about 10% to about 40%, about 15% to about 50%, about 15% to about 40%, about 20% to about 60%, or about 20% to about 70% stem cell memory and central memory cells.
[0224] In some embodiments, engineered immune cells expressing antigen-specific CARs on their surface membranes are enriched for T cells. CM and / or T SCM cells, such that the engineered immune cells include at least about 60%, 65%, 70%, 75% or 80% of the combined T CM and T SCM In some embodiments, engineered immune cells expressing antigen-specific CARs at their cell surface membranes are enriched for T cells. CM Cells and / or T SCM cells, such that the engineered immune cells include at least about 70% of the combined T CM Cells and T SCM In some embodiments, engineered immune cells expressing antigen-specific CARs at their cell surface membranes are enriched for T cells. CM Cells and / or T SCM cells, such that the engineered immune cells include at least about 75% of the combined T CMCells and / or T SCM cell.
[0225] In some embodiments, the engineered immune cell is an inflammatory T lymphocyte expressing CAR. In some embodiments, the engineered immune cell is a cytotoxic T lymphocyte expressing CAR. In some embodiments, the engineered immune cell is a regulatory T lymphocyte expressing CAR. In some embodiments, the engineered immune cell is an auxiliary T lymphocyte expressing CAR.
[0226] Genetic modification of CAR T cells
[0227] In some embodiments, the engineered immune cells derived from donor cells with certain biomarker profiles according to the present disclosure may include one or more destroyed or inactivated genes. In some embodiments, the genes of the target antigen (e.g., EGFRvIII, Flt3, WT-1, CD20, CD23, CD30, CD38, CD33, CD133, MHC-WT1, TSPAN10, MHC-PRAME, Liv1, ADAM10, CHRNA2, LeY, NKGD2D, CS1, CD44v6, ROR1, Claudin-18.2, Muc17, FAPα, Ly6G6D, c6orf23, G6D, MEGT1, NG25, CD19, BCMA, FLT3, CD70, DLL3 or CD34, CD70) may be In order to be knocked out to introduce a CAR targeting the same antigen (e.g., EGFRvIII, Flt3, WT-1, CD20, CD23, CD30, CD38, CD33, CD133, MHC-WT1, TSPAN10, MHC-PRAME, Liv1, ADAM10, CHRNA2, LeY, NKGD2D, CS1, CD44v6, ROR1, Claudin-18.2, Muc17, FAPα, Ly6G6D, c6orf23, G6D, MEGT1, NG25, CD19, BCMA, FLT3, CD70, DLL3 or CD34, CD70 CAR), thereby avoiding induction of CAR activation. As described herein, in some embodiments, the engineered immune cell according to the present disclosure includes a destroyed or inactivated gene, the gene is selected from the group consisting of the following: MHC1 (β2M), MHC2 (CIITA), EGFRvIII, Flt3, WT-1, CD20, CD23, CD30, CD38, CD33, CD133, MHC-WT1, TSPAN10, MHC-PRAME, Liv1, ADAM10, CHRNA2, LeY, NKGD2D, CS1, CD44v6, ROR1, Claudin-18.2, Muc17, FAPα, Ly6G6D, c6orf23, G6D, MEGT1, NG25, CD19, BCMA, FLT3, CD70, DLL3 or CD34, CD70, TCRα and TCRβ, and / or expresses CAR or multi-chain CAR. In some embodiments, the cell includes multi-chain CAR.In some embodiments, the isolated cells comprise two disrupted or inactivated genes selected from the group consisting of CD52 and TCRα, CDR52 and TCRβ, PD-1 and TCRα, PD-1 and TCRβ, MHC-1 and TCRα, MHC-1 and TCRβ, MHC2 and TCRα, MHC2 and TCRβ, and / or express CAR or multi-chain CAR.
[0228] In some embodiments, the engineered immune cells derived from donor cells with specific biomarker characteristics according to the present disclosure include a destroyed or inactivated gene selected from the group consisting of CD52, DLL3, GR, PD-1, CTLA-4, LAG3, TIM3, BTLA, BY55, TIGIT, B7H5, LAIR1, SIGLEC10, 2B4, HLA, TCRα and TCRβ, and / or express CAR, multi-chain CAR and / or pTα transgene. In some embodiments, the isolated cells include polynucleotides encoding polypeptides including multi-chain CARs. In some embodiments, the isolated cells according to the present disclosure comprise two disrupted or inactivated genes selected from the group consisting of CD52 and GR, CD52 and TCRα, CDR52 and TCRβ, DLL3 and CD52, DLL3 and TCRα, DLL3 and TCRβ, GR and TCRα, GR and TCRβ, TCRα and TCRβ, PD-1 and TCRα, PD-1 and TCRβ, CTLA-4 and TCRα, CTLA-4 and TCRβ, LAG3 and TCRα, LAG3 and TCRβ , TIM3 and TCRα, Tim3 and TCRβ, BTLA and TCRα, BTLA and TCRβ, BY55 and TCRα, BY55 and TCRβ, TIGIT and TCRα, TIGIT and TCRβ, B7H5 and TCRα, B7H5 and TCRβ, LAIR1 and TCRα, LAIR1 and TCRβ, SIGLEC10 and TCRα, SIGLEC10 and TCRβ, 2B4 and TCRα, 2B4 and TCRβ, and / or expression of CAR (including multi-chain CAR and / or pTα transgene). In some embodiments, the method includes disrupting or inactivating one or more genes by introducing into the donor cell a nuclease that can selectively inactivate the gene by selective DNA cutting. In some embodiments, the nuclease can be, for example, a zinc finger nuclease (ZFN), a megaTAL nuclease, a large range nuclease, a transcription activator-like effector nuclease (TALE-nuclease or ) or CRISPR (e.g., Cas9 or Cas12) endonucleases.
[0229] In some embodiments, the TCR is rendered non-functional in a cell according to the present disclosure by destroying or inactivating the TCRα gene and / or the TCRβ gene. In some embodiments, a method for obtaining modified cells derived from an individual is provided, wherein the cells can proliferate independently of the major histocompatibility complex (MHC) signaling pathway. Modified cells that can proliferate independently of the MHC signaling pathway and are easily obtained by this method are encompassed within the scope of the present disclosure. The modified cells disclosed herein can be used to treat host-versus-graft (HvG) rejection and graft-versus-host disease (GvHD) in patients in need; therefore, within the scope of the present disclosure is a method for treating host-versus-graft (HvG) rejection and graft-versus-host disease (GvHD) in patients in need, the method comprising treating the patient by administering to the patient an effective amount of modified cells, the modified cells comprising destroyed or inactivated TCRα and / or TCRβ genes.
[0230] The present disclosure provides a method for determining the purity of an engineered immune cell group lacking or having reduced endogenous TCR expression. In some embodiments, the engineered immune cell comprises less than 5.0%, less than 4.0%, less than 3.0% TCR+ cells, less than 2.0% TCR+ cells, less than 1.0% TCR+ cells, less than 0.9% TCR+ cells, less than 0.8% TCR+ cells, less than 0.7% TCR+ cells, less than 0.6% TCR+ cells, less than 0.5% TCR+ cells, less than 0.4% TCR+ cells, less than 0.3% TCR+ cells, less than 0.2% TCR+ cells or less than 0.1% TCR+ cells. This colony can be the product of the disclosed method.
[0231] In some embodiments, immune cells are engineered to have tolerance to one or more chemotherapeutic drugs. The chemotherapeutic drug may be, for example, a purine nucleotide analog (PNA), so that immune cells are suitable for cancer treatment combined with adoptive immunotherapy and chemotherapy. Exemplary PNAs include, for example, clofarabine, fludarabine, cyclophosphamide, and cytarabine, in separate or combined forms. PNA is metabolized into single, two, and triphosphate PNAs by deoxycytidine kinase (dCK). Its triphosphate form competes with ATP for DNA synthesis, serves as a pro-apoptotic agent, and is an effective inhibitor of the ribonucleotide reductase (RNR) involved in the production of trinucleotides.
[0232] In some embodiments, the isolated cells or cell lines of the present disclosure may include pTalpha or a functional variant thereof. In some embodiments, the isolated cells or cell lines may be further genetically modified by disrupting or inactivating the TCRalpha gene.
[0233] The disclosure also provides engineered immune cells (derived from donor cells with certain biomarker profiles) comprising any CAR nucleotides described herein. In some embodiments, CAR can be introduced into immune cells as transgenes via plasmid vectors. In some embodiments, plasmid vectors may also contain, for example, selection markers that provide identification and / or selection of cells receiving the vector.
[0234] After the polynucleotide encoding the CAR polypeptide is introduced into the cell, the CAR polypeptide can be synthesized in situ in the cell. Alternatively, the CAR polypeptide can be produced extracellularly and then introduced into the cell. The method of introducing a polynucleotide construct into a cell is known in the art. In some embodiments, a stable transformation method (e.g., using a lentiviral vector) can be used to integrate a polynucleotide construct into the genome of the cell. In other embodiments, a transient transformation method can be used to transiently express a polynucleotide construct and a polynucleotide construct that is not integrated into the genome of the cell. In other embodiments, a viral-mediated method can be used. Polynucleotides can be introduced into cells by any suitable means, such as recombinant viral vectors (e.g., retroviruses, adenoviruses), liposomes, etc. Transient transformation methods include, for example, but not limited to microinjection, electroporation, or particle bombardment. The polynucleotide may be included in a vector, such as a plasmid vector or a viral vector.
[0235] In some embodiments, an isolated nucleic acid is provided, comprising a promoter operably linked to a first polynucleotide encoding an antigen binding domain, at least one co-stimulatory molecule and an activation domain. In some embodiments, the nucleic acid construct is contained in a viral vector. In some embodiments, the viral vector is selected from the group consisting of: a retroviral vector, a murine leukemia virus vector, a SFG vector, an adenoviral vector, a lentiviral vector, an adeno-associated virus (AAV) vector, a herpes virus vector and a vaccinia virus vector. In some embodiments, the nucleic acid is contained in a plasmid.
[0236] In some embodiments, the isolated nucleic acid construct is contained in a viral vector and is introduced into the genome of the engineered immune cell by random integration (e.g., lentiviral or retroviral mediated random integration). In some embodiments, the isolated nucleic acid construct is contained in a viral vector or a non-viral vector and is introduced into the genome of the engineered immune cell by site-specific integration (e.g., adenovirus mediated site-specific integration).
[0237] 3. Preparation of engineered immune cells (including CAR T cells)
[0238] Provided herein is a method for analyzing or determining various properties of donor cells from donor cell groups and / or engineered immune cells from immune cell groups (including engineered immune cells, such as CAR expression or CAR+ cells). As described herein, engineered immune cells, such as CAR T cells, can be modified to reduce or eliminate the expression or activity of endogenous TCR, and the remaining TCR+ engineered immune cells can be eliminated at the end of production according to the methods described herein. The present disclosure provides a method for characterizing or analyzing engineered immune cell groups to characterize medicines or as part of a preparation process. The present disclosure also provides a method for analyzing or determining other properties of engineered immune cells to characterize medicines or as part of a preparation process, such as efficacy or versatility. In some embodiments, engineered immune cells (such as CAR T cells) are prepared according to good manufacturing practices (GMP).
[0239] Many known techniques can be used to prepare polynucleotides, polypeptides, vectors, antigen binding domains, immune cells, compositions, etc. according to the present disclosure.
[0240] Prior to in vitro manipulation or genetic modification of the immune cells described herein, the cells can be obtained from a subject. Cells expressing CAR can be derived from allogeneic or autologous sources and can be knocked out of endogenous TCR as described herein.
[0241] a. Source Materials
[0242] In some embodiments, immune cells include T cells. T cells can be obtained from a variety of sources, including peripheral blood mononuclear cells (PBMC), bone marrow, lymph node tissue, cord blood, thymus tissue, tissue from the site of infection, ascites, pleural effusion, spleen tissue and tumors. In certain embodiments, any number of techniques known to the skilled person can be used, such as FICOLL TM Isolate and obtain T cells from a volume of blood collected from a subject.
[0243] Cells can be obtained from the circulating blood of an individual by apheresis. The apheresis product typically contains lymphocytes, including T cells, monocytes, granulocytes, B cells, other nucleated leukocytes, red blood cells, and platelets. In certain embodiments, the cells collected by apheresis can be washed to remove plasma components and then placed in an appropriate buffer or culture medium for subsequent processing.
[0244] In certain embodiments, for example, using PERCOLL TMGradient centrifugation, by lysing red blood cells and consuming monocytes, separates T cells from PBMC. Specific subpopulations of T cells, (e.g., CD28+, CD4+, CD45RA- and CD45RO+T cells or CD28+, CD4+, CDS+, CD45RA-, CD45RO+ and CD62L+T cells) can be further separated by positive or negative selection techniques known in the art. For example, the enrichment of T cell colonies by negative selection can be achieved with a combination of antibodies for surface markers unique to negatively selected cells. One of the methods used herein is to sort and / or select cells by negative magnetic immunoadhesion or flow cytometry, which uses a mixture of monoclonal antibodies for cell surface markers present on negatively selected cells. For example, in order to enrich for CD4+ cells by negative selection, a mixture of monoclonal antibodies generally includes antibodies for CD14, CD20, CD11b, CD16, HLA-DR and CD8. Flow cytometry and cell sorting can also be used to separate the cell colonies of interest for use in the present disclosure.
[0245] Using methods as described herein, PBMC can be directly used for the genetic modification of immune cells (such as CAR or TCR).In certain embodiments, after separating PBMC, T lymphocytes can be further separated, and cytotoxicity and helper T lymphocytes can be sorted as primary, memory and effector T cell subsets before or after genetic modification and / or amplification.In some embodiments, CD8+ cells are further sorted as primary, stem cell memory, central memory and effector cells by identifying the cell surface antigens related to each of these CD8+ cell types.In some embodiments, the expression of the phenotypic markers of central memory T cells includes CD27, CD45RA, CD45RO, CD62L, CCR7, CD28, CD3 and CD127 and is negative for granzyme B.In some embodiments, stem cell memory T cells are CD45RO-, CD62L+, CD8+T cells.In some embodiments, central memory T cells are CD45RO+, CD62L+, CD8+T cells. In some embodiments, effector T cells are negative for CD62L, CCR7, CD28, and CD127, and positive for granzyme B and perforin. In certain embodiments, CD4+ T cells are further sorted into subpopulations. For example, CD4+ T helper cells can be sorted into naive, central memory, and effector cells by identifying cell populations with cell surface antigens.
[0246] b. Stem cell-derived immune cells
[0247] In some embodiments, immune cells can be derived from embryonic stem (ES) cells or induced pluripotent stem (iPS) cells. Suitable HSC, mesenchymal cells, iPS cells and other types of stem cells can be cultivated into immortal cell lines or directly isolated from patients. Various methods for isolating, producing and / or cultivating stem cells are known in the art and can be used to practice the present disclosure.
[0248] In some embodiments, immune cells are induced pluripotent stem cells (iPSC) derived from reprogrammed T cells. In some embodiments, the source material can be an induced pluripotent stem cell (iPSC) derived from T cells or non-T cells. The source material can be an embryonic stem cell. The source material can be a B cell, or any other cell from peripheral blood mononuclear cell isolates, hematopoietic progenitor cells, hematopoietic stem cells, mesenchymal stem cells, adipose stem cells, or any other somatic cell type.
[0249] c. Genetic modification of isolated cells
[0250] The donor immune cells (eg, T cells) of the donor immune cell population can be genetically modified using known methods after separation, or the donor immune cells can be activated and amplified (or differentiated in the case of progenitor cells) in vitro before being genetically modified. In some embodiments, the separated donor immune cells are genetically modified to reduce or eliminate the expression or activity of endogenous TCRα and / or CD52. In some embodiments, cells are genetically modified using gene editing techniques (eg, CRISPR / Cas9, CRISPR / Cas12a, zinc finger nuclease (ZFN), TALEN, homing endonuclease, large range nuclease) to reduce or eliminate the expression or activity of endogenous proteins (eg, TCRα and / or CD52). In another embodiment, immune cells (eg, T cells) are genetically modified with a chimeric antigen receptor as described herein (eg, transduced with a viral vector comprising one or more nucleotide sequences encoding CAR), and then activated and / or amplified in vitro.
[0251] Following genetic modification to reduce or eliminate the expression or activity of endogenous genes (e.g., endogenous TCRα and / or CD52), in order to provide engineered immune cells derived from donor cells, the engineered immune cells can be depleted (according to the methods described herein) of engineered immune cells that express one or more unwanted biomarkers (e.g., one or more of HLA-DR, TIGIT, CD16, CD56, and any combination thereof). Figure 5Depicted is a workflow for preparing engineered immune cells, including a knockout step after a step of reducing / eliminating the expression / activity of an endogenous gene (knockout followed by knockout based on biomarker analysis). The knockout step based on biomarker analysis can be performed at another time point, such as before activation or after activation.
[0252] Certain methods for making the constructs and engineered immune cells of the present disclosure are described in PCT Application No. PCT / US15 / 14520, the contents of which are incorporated herein by reference in their entirety.
[0253] It should be understood that PBMC may further include other cytotoxic lymphocytes, such as NK cells or NKT cells.The expression vector carrying the coding sequence of the chimeric receptor as disclosed herein can be introduced into a population of human donor T cells, NK cells or NKT cells.Flow cytometry can be used to sort the T cells carrying the successful transduction of the expression vector to separate CD3 positive T cells, and then further proliferate to increase the number of these CAR expression T cells except for the cell activation of other methods as described elsewhere herein known in the art using anti-CD3 antibodies and IL-2 or other methods as described herein.Standard procedures are used to cryopreserve T cells expressing CAR, to store and / or prepare for human individuals.In one embodiment, in the absence of non-human animal derived products, such as fetal bovine serum (fetal calfserum / fetal bovine serum), T cells are transduced in vitro, cultured and / or amplified.
[0254] In order to clone a polynucleotide, the vector can be introduced into a host cell (isolated host cell) to allow replication of the vector itself, and thereby amplify copies of the polynucleotide contained therein. The cloning vector may contain sequence components, generally including but not limited to a replication origin, a promoter sequence, a transcription initiation sequence, an enhancer sequence, and a selectable marker. These elements may be selected as appropriate by a person of ordinary skill in the art. For example, a replication origin may be selected to promote autonomous replication of the vector in a host cell.
[0255] In certain embodiments, the disclosure provides an isolated host cell containing a vector provided herein. The host cell containing the vector can be used for expression or cloning of the polynucleotide contained in the vector. Suitable host cells can include but are not limited to prokaryotic cells, fungal cells, yeast cells or higher eukaryotic cells, such as mammalian cells, particularly human cells.
[0256] The vector can be introduced into the host cell using any suitable method known in the art, including but not limited to DEAE-dextran mediated delivery, calcium phosphate precipitation method, cationic lipid mediated delivery, liposome mediated transfection, electroporation, gene gun method, receptor mediated gene delivery, delivery mediated by polylysine, histone, chitosan and peptide. Standard methods for transfection and transformation of cells for expressing the vector of interest are well known in the art. In another embodiment, a mixture of different expression vectors can be used for a donor population of genetically modified immune effector cells, wherein each vector encodes a different CAR as disclosed herein. The resulting transduced immune effector cells form a mixed population of engineered cells, wherein a certain proportion of engineered cells express more than one different CAR.
[0257] In one embodiment, the present disclosure provides a method for storing genetically engineered cells expressing CAR or TCR. This involves cryopreservation of immune cells so that the cells remain viable after thawing. A portion of the immune cells expressing CAR can be cryopreserved by methods known in the art to provide a permanent source of such cells for future treatment of patients with malignant tumors. When necessary, cryopreserved transformed immune cells can be thawed, grown, and expanded to obtain more such cells.
[0258] In some embodiments, cells are formulated by first collecting the cells from their culture medium, and then washing and concentrating the cells in a culture medium and container system (a "pharmaceutically acceptable" carrier) suitable for administration in a therapeutically effective amount. Suitable infusion media can be any isotonic medium formulation, typically saline Normosol TM R (Abbott) or Plasma-Lyte TM A (Baxter), but 5% dextrose in water or Ringer's lactate may also be used. The infusion medium may be supplemented with human serum albumin.
[0259] d. Allogeneic CAR T cells
[0260] The process for preparing allogeneic CAR T therapy involves collecting healthy, selected, screened and tested donor immune cells, including T cells, from healthy donors. Then, the T cells of the donor immune cells are engineered to express CAR, which recognizes certain cell surface proteins expressed in blood or solid tumors. Allogeneic T cells are gene-edited to reduce the risk of graft-versus-host disease (GvHD) and prevent allogeneic rejection. T cell receptor genes (e.g., TCRα, TCRβ) are knocked out to avoid GvHD. The CD52 gene can be knocked out to make the CAR T product resistant to anti-CD52 antibody treatment. Therefore, anti-CD52 antibody treatment can be used to suppress the host immune system and allow CAR T to remain implanted to achieve a complete therapeutic effect. The engineered T cells then undergo further processing, which may optionally include a depletion step to remove unwanted T cells that express the biomarker profiles described herein (e.g., unwanted T cells that express one or more of HLA-DR, TIGIT, CD16, CD56, and any combination thereof) as well as a purification step, and are ultimately cryopreserved in vials for delivery to patients.
[0261] e. Autologous CAR T cells
[0262] Autologous chimeric antigen receptor (CAR) T cell therapy involves collecting the patient's own cells (e.g., leukocytes, including T cells) and genetically engineering the T cells to express the CAR of the target expressed on the cell surface of one or more specific cancer cells and kill cancer cells. Engineered T cells can optionally undergo a knockout step to remove unwanted T cells expressing biomarker profiles described herein (e.g., expressing one or more unwanted T cells in HLA-DR, TIGIT, CD16, CD56, and any combination thereof). The engineered cells are then cryopreserved and subsequently applied to the patient.
[0263] 4. In vitro sorting method
[0264] In some embodiments, a method for in vitro sorting of an immune cell population is provided, wherein a subpopulation of the immune cell population comprises an engineered immune cell expressing an antigen-specific CAR, wherein the antigen-specific CAR comprises an epitope (e.g., an exemplary mimetic position sequence) specific to a monoclonal antibody. The method comprises contacting an immune cell population with a monoclonal antibody specific to an epitope, and selecting immune cells bound to the monoclonal antibody to obtain a cell population enriched in an engineered immune cell expressing an antigen-specific CAR.
[0265] In some embodiments, the monoclonal antibody specific for the epitope is optionally conjugated to a fluorophore. In this embodiment, the step of selecting cells that bind to the monoclonal antibody can be accomplished by fluorescence activated cell sorting (FACS).
[0266] In some embodiments, the monoclonal antibody specific for the epitope is optionally conjugated to magnetic particles. In this embodiment, the step of selecting cells that bind to the monoclonal antibody can be performed by magnetic activated cell sorting (MACS).
[0267] In some embodiments, the mAb used in the method of sorting CAR-expressing immune cells is selected from alemtuzumab, ibritumomab tiuxetan, muromonab-CD3, tositumomab, abciximab, basiliximab, brentuximab, cetuximab, infliximab, rituximab, bevacizumab, certolizumab pegol, daclizumab, eculizumab, efalizumab, gemtuzumab, In some embodiments, the mAb is rituximab. In another embodiment, the mAb is QBEND-10. In other embodiments, the mAb binds to TCRα or TCRb.
[0268] In some embodiments, the CAR-expressing immune cell population obtained when using the method described above for in vitro sorting of immune cells expressing CAR comprises at least 70%, 75%, 80%, 85%, 90%, 95% of immune cells expressing CAR. In some embodiments, the CAR-expressing immune cell population obtained when using the method for in vitro sorting of immune cells expressing CAR comprises at least 85% of immune cells expressing CAR.
[0269] In some embodiments, the immune cell group expressing CAR obtained when using the method for in vitro sorting of immune cells expressing CAR described above shows an increased in vitro cytotoxic activity compared to the initial (unsorted) cell group. In some embodiments, the in vitro cytotoxic activity increases by 10%, 20%, 30%, 40% or 50%. In some embodiments, the immune cell is a T cell.
[0270] In some embodiments, the mAb is previously bound to a support or surface. Non-limiting examples of solid supports can include beads, agarose beads, magnetic beads, plastic well plates, glass well plates, ceramic well plates, columns, or cell culture bags.
[0271] Immune cells expressing CAR to be administered to a recipient can be enriched in vitro from a source population. Methods for expanding a source population can include using a combination of density centrifugation, immunomagnetic bead purification, affinity chromatography, and fluorescence activated cell sorting to select cells expressing antigens such as the CD34 antigen.
[0272] Flow cytometry can be used to quantify specific cell types within a cell population. In general, flow cytometry is a method that quantifies components or structural features of cells, primarily by optical means. Since different cell types can be distinguished by quantifying structural features, flow cytometry and cell sorting can be used to count and sort cells of different phenotypes in a mixture.
[0273] In some embodiments, the method for sorting T cells expressing CAR is magnetic activated cell sorting (MACS). Magnetic activated cell sorting (MACS) is a method for separating various cell populations according to cell surface antigens (e.g., CD molecules) by using superparamagnetic nanoparticles and columns. MACS can be used to obtain pure cell populations. Cells in a single cell suspension can be magnetically labeled with microbeads. The sample is applied to a column consisting of ferromagnetic spheres, which is covered with a cell-friendly coating that allows rapid and gentle separation of cells. Unlabeled cells pass through and magnetically labeled cells are retained in the column. The effluent can be collected as an unlabeled cell fraction. After the washing step, the column is removed from the separator, and the magnetically labeled cells are eluted from the column.
[0274] Detailed protocols for purifying specific cell populations (such as T cells) can be found in Basu S et al. (2010). (Basu S, Campbell HM, Dittel BN, Ray A. Purification of specific cell population by fluorescence activated cell sorting (FACS). J Vis Exp. (41): 1546).
[0275] 5. Pharmaceutical compositions and therapies
[0276] In some embodiments, the engineered immune cells described herein are formulated by first collecting the cells from their culture medium, and then washing and concentrating the cells in a culture medium and container system (a "pharmaceutically acceptable" carrier) suitable for administration in a therapeutically effective amount. Suitable infusion media can be any isotonic medium formulation, typically saline Normosol TM R (Abbott) or Plasma-Lyte TM A (Baxter), but 5% dextrose in water or Ringer's lactate may also be used. The infusion medium may be supplemented with human serum albumin.
[0277] In embodiments, the desired therapeutic amount of cells in the composition is typically at least 2 cells (e.g., at least 1 CD8+ central or stem cell memory T cell and at least 1 CD4+ helper T cell subset; or two or more CD8+ central or stem cell memory T cells; or two or more CD4+ helper T cell subsets) or more typically greater than 10 2 cells, and up to and including 10 6 cells, up to and including 10 7 , 10 8 or 10 9 cells, and can be more than 10 10 The number of cells will depend on the intended use of the composition and the type of cells contained therein. The desired cell density is generally greater than 10 6 cells / ml and usually greater than 10 7 cells / ml, usually 10 8 Clinically relevant numbers of immune cells can be assigned to cells that accumulate to or exceed 10 5 , 10 6 , 10 7 , 10 8 , 10 9 , 10 10 , 10 11 or 10 12 In some aspects of the present disclosure, particularly since all infused cells will be redirected to a specific target antigen, administration may be performed over a period of about 10 5 / kg or about 10 6 / kg (10 per patient 6 -10 11) range. CAR therapy can be administered multiple times at doses within these ranges. The cells can be autologous, allogeneic, or xenogeneic to the patient being treated.
[0278] The CAR expressing cell colony of the present disclosure can be administered alone or in the form of a pharmaceutical composition combined with a diluent and / or with other components (such as IL-2 or other cytokines or cell colonies). The pharmaceutical composition of the present disclosure may include CAR expression or TCR expression cell colonies, such as T cells described herein, combined with one or more pharmaceutically or physiologically acceptable carriers, diluents or excipients. Such compositions may include buffers, such as neutral buffered saline, phosphate buffered saline, etc.; carbohydrates, such as glucose, mannose, sucrose or dextran, mannitol; protein; polypeptides or amino acids, such as glycine; antioxidants; chelating agents, such as EDTA or glutathione; adjuvants (e.g., aluminum hydroxide); and preservatives. The present disclosure composition is preferably formulated for intravenous administration.
[0279] Pharmaceutical compositions (solutions, suspensions, etc.) may contain one or more of the following: sterile diluents, such as water for injection, saline solution (preferably physiological saline), Ringer's solution, isotonic sodium chloride; fixed oils, such as synthetic mono- or diglycerides that may serve as solvents or suspension media; polyethylene glycol, glycerol, propylene glycol or other solvents; antibacterial agents, such as benzyl alcohol or methyl paraben; antioxidants, such as ascorbic acid or sodium bisulfite; chelating agents, such as ethylenediaminetetraacetic acid; buffers, such as acetates, citrates or phosphates and agents for adjusting tonicity, such as sodium chloride or dextrose. Parenteral formulations may be sealed in ampoules, disposable syringes or multiple-dose vials made of glass or plastic. Injectable pharmaceutical compositions are preferably sterile.
[0280] 6. Treatment Methods
[0281] The present disclosure includes a method for treating or preventing a patient's disease (e.g., cancer), the method comprising administering an effective amount of engineered immune cells (e.g., CAR T cells or engineered immune cells comprising CAR disclosed herein) derived from donor cells having a biomarker spectrum as described herein to patients in need. In some embodiments, an effective amount of CAR T cells or engineered immune cells have been analyzed for various properties according to the methods described in the present disclosure. In some embodiments, various properties (such as specific biomarker characteristics, efficacy, or versatility) have been analyzed for CART cell medicines for therapeutic use according to the methods described in the present disclosure. In some embodiments, CART cells are TCR-CAR T cells, and various properties of CAR T drug products for therapeutic use have been analyzed according to the methods described in the present disclosure, such as the number or percentage of remaining TCR+CAR T cells and / or efficacy or versatility.
[0282] Methods for treating diseases or disorders including cancer are provided. In some embodiments, the present disclosure relates to generating a T cell-mediated immune response in an individual, comprising administering an effective amount of an engineered immune cell of the present application to the individual. In some embodiments, the T cell-mediated immune response is directed to a target cell or cell. In some embodiments, the engineered immune cell includes a chimeric antigen receptor (CAR). In some embodiments, the target cell is a tumor cell. In some aspects, the present disclosure includes a method for treating or preventing a malignant tumor, the method comprising administering an effective amount of at least one separated antigen binding domain described herein to an individual in need. In some aspects, the present disclosure includes a method for treating or preventing a malignant tumor, the method comprising administering an effective amount of at least one immune cell to a subject in need, wherein the immune cell includes at least one chimeric antigen receptor, a T cell receptor and / or a separated antigen binding domain as described herein. The immune cells containing CAR disclosed herein can be used to treat malignant tumors involving abnormal expression of biomarkers. In some embodiments, the CAR-containing immune cells of the present disclosure can be used to treat small cell lung cancer, melanoma, low-grade glioma, glioblastoma, medullary thyroid carcinoma, carcinoid, scattered neuroendocrine tumors in the pancreas, bladder and prostate, testicular cancer and lung adenocarcinoma with neuroendocrine features. In an exemplary embodiment, CAR-containing immune cells (such as CAR-T cells of the present disclosure) are used to treat small cell lung cancer.
[0283] Also provided are methods for reducing tumor size in a subject comprising administering to the subject an engineered cell of the disclosure, wherein the cell comprises a chimeric antigen receptor that comprises an antigen binding domain and binds to an antigen on the tumor.
[0284] In some embodiments, the subject suffers from a solid tumor or a hematological malignancy, such as a lymphoma or a leukemia. In some embodiments, the engineered cells are delivered to the tumor bed. In some embodiments, the cancer is present in the bone marrow of an individual. In some embodiments, the engineered cells are autologous immune cells, such as autologous T cells. In some embodiments, the engineered cells are allogeneic immune cells, such as allogeneic T cells. In some embodiments, the engineered cells are heterologous immune cells, such as heterologous T cells. In some embodiments, the engineered cells of the present application are transfected or transduced in vivo. In other embodiments, the engineered cells are transfected or transduced ex vivo. As used herein, the term "in vitro cell" refers to any cell cultured ex vivo.
[0285] A therapeutic agent, for example, a "therapeutically effective amount", "effective dose", "effective amount", or "therapeutically effective dose" of an engineered CART cell is any amount that, when used alone or in combination with another therapeutic agent, protects an individual from the onset of disease or promotes disease regression, as evidenced by a reduction in the severity of disease symptoms, an increase in the frequency and duration of disease-free periods, or the prevention of disorders or disabilities caused by disease pain. The ability of a therapeutic agent to promote disease regression can be evaluated using a variety of methods known to skilled practitioners, such as in human individuals during clinical trials, in animal model systems predicting efficacy in humans, or by analyzing the activity of an agent in an in vitro assay.
[0286] The terms "patient" and "subject" are used interchangeably and include human and non-human animal subjects, as well as those with a formally diagnosed condition, those without a formally recognized disorder, those under medical observation, those at risk of developing the disease, etc.
[0287] The terms "treat" and "treatment" encompass therapeutic treatment, prophylactic treatment, and applications in which the risk of a disorder or other risk factor being developed is reduced in an individual. Treatment does not require a complete cure of the disorder and encompasses embodiments in which symptoms or potential risk factors are reduced. The term "prevention" does not require 100% elimination of the likelihood of an event occurring. Rather, it means that the likelihood of an event occurring has been reduced in the presence of a compound or method.
[0288] The desired therapeutic amount of cells in the composition is generally at least 2 cells (e.g., at least 1 CD8+ central memory T cell and at least 1 CD4+ helper T cell subset), or more usually greater than 10 2 cells, and up to 10 6 , up to and including 10 8 or 10 9cells, and can exceed 10 10 The number of cells will depend on the intended use of the composition and the type of cells contained therein. The desired cell density is generally greater than 10 6 cells / ml and usually greater than 10 7 cells / ml, usually 108 cells / ml or greater. Clinically relevant numbers of immune cells can be assigned to cells with a cumulative count equal to or greater than 10 5 , 10 6 , 10 7 , 10 8 , 10 9 , 10 10 , 10 11 or 10 12 In some aspects of the present disclosure, particularly since all infused cells will be redirected to a specific target antigen, 10 6 / kg(10 6 -10 11 The CAR therapy may be administered multiple times at doses within these ranges. The cells may be autologous, allogeneic, or xenogeneic to the patient being treated.
[0289] In some embodiments, the therapeutically effective amount of CAR T cells is about 1×10 5 cells / kg, about 2X 10 5 cells / kg, about 3X 10 5 cells / kg, about 4X 10 5 cells / kg, about 5X 10 5 cells / kg, about 6X 10 5 cells / kg, about 7X 10 5 cells / kg, about 8X 10 5 cells / kg, about 9X 10 5 cells / kg, 2X 10 6 cells / kg, about 3X 10 6 cells / kg, about 4X 10 6 cells / kg, about 5X 10 6 cells / kg, about 6X 10 6 cells / kg, about 7X 10 6 cells / kg, about 8X 10 6 cells / kg, about 9X 10 6 cells / kg, about 1X 10 7 cells / kg, about 2X 10 7 cells / kg, about 3X 107 cells / kg, about 4X 10 7 cells / kg, about 5X 10 7 cells / kg, about 6X 10 7 cells / kg, about 7X 10 7 cells / kg, about 8X 10 7 cells / kg or about 9X 10 7 cells / kg.
[0290] In some embodiments, the target dose of CAR+ / CAR-T+ / TCR+ cells is 1×10 6 -2×10 8 cells / kg, for example 2×10 6 In some embodiments, the dosage of the present invention is within the range of 10 cells / kg. It should be understood that administration above and below this range may be suitable for certain subjects, and appropriate administration levels may be determined by a healthcare provider as needed. In addition, multiple doses of cells may be provided according to the present disclosure.
[0291] In some aspects, the disclosure includes pharmaceutical compositions comprising at least one antigen binding domain as described herein and a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition further comprises an additional active agent.
[0292] The CAR expressing cell colony of the present disclosure can be administered alone or in the form of a pharmaceutical composition combined with a diluent and / or with other components (such as IL-2 or other cytokines or cell colonies). The pharmaceutical composition of the present disclosure may include CAR expression or TCR expression cell colonies, such as T cells described herein, combined with one or more pharmaceutically or physiologically acceptable carriers, diluents or excipients. Such compositions may include buffers, such as neutral buffered saline, phosphate buffered saline, etc.; carbohydrates, such as glucose, mannose, sucrose or dextran, mannitol; protein; polypeptides or amino acids, such as glycine; antioxidants; chelating agents, such as EDTA or glutathione; adjuvants (e.g., aluminum hydroxide); and preservatives. The present disclosure composition is preferably formulated for intravenous administration.
[0293] Pharmaceutical compositions (solutions, suspensions, etc.) may contain one or more of the following: sterile diluents, such as water for injection, saline solution (preferably physiological saline), Ringer's solution, isotonic sodium chloride; fixed oils, such as synthetic mono- or diglycerides that may serve as solvents or suspension media; polyethylene glycol, glycerol, propylene glycol or other solvents; antibacterial agents, such as benzyl alcohol or methyl paraben; antioxidants, such as ascorbic acid or sodium bisulfite; chelating agents, such as ethylenediaminetetraacetic acid; buffers, such as acetates, citrates or phosphates and agents for adjusting tonicity, such as sodium chloride or dextrose. Parenteral formulations may be sealed in ampoules, disposable syringes or multiple-dose vials made of glass or plastic. Injectable pharmaceutical compositions are preferably sterile.
[0294] In some embodiments, when applied to a patient, an engineered immune cell expressing any one of the antigen-specific CARs described herein on the cell surface can reduce, kill or lyse the patient's endogenous antigen-expressing cells. In one embodiment, the reduction or lysis percentage of the cell of the antigen-expressing endogenous cell or cell line of any one of the engineered immune cells expressing antigens described herein is at least about or greater than 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95%. In one embodiment, the reduction or lysis percentage of the endogenous cells expressing antigen or the cell line expressing antigen produced by the engineered immune cells expressing antigen-specific CAR is about 5% to about 95%, about 10% to about 95%, about 10% to about 90%, about 10% to about 80%, about 10% to about 70%, about 10% to about 60%, about 10% to about 50%, about 10% to about 40%, about 20% to about 90%, about 20% to about 80%, about 20% to about 70%, about 20% to about 60%, about 20% to about 50%, about 25% to about 75% or about 25% to about 60%. In one embodiment, the cell expressing endogenous antigen is the bone marrow cell expressing endogenous antigen.
[0295] In one embodiment, the reduction or percentage of target cells (e.g., antigen-expressing cell lines) generated by engineered immune cells expressing an antigen-specific CAR of the present disclosure on the cell surface membrane can be measured using the assays disclosed herein.
[0296] The method may further comprise administering one or more chemotherapeutic agents. In certain embodiments, the chemotherapeutic agent is a lymphocyte depletion (pretreatment) chemotherapeutic agent. For example, a method of conditioning a patient in need of T cell therapy comprises administering to the patient a prescribed beneficial dose of cyclophosphamide (at 200 mg / m 2 / day and 2000mg / m 2 / day, about 100mg / m 2 / day and about 2000mg / m 2 / day; for example, about 100 mg / m 2 / day, about 200mg / m 2 / day, about 300mg / m 2 / day, about 400mg / m 2 / day, about 500mg / m 2 / day, about 600mg / m 2 / day, about 700mg / m 2 / day, about 800mg / m 2 / day, about 900mg / m 2 / day, about 1000mg / m 2 / day, about 1500mg / m 2 / day or about 2000mg / m 2 / day) and the indicated dose of fludarabine (at 20 mg / m 2 / day and 900mg / m 2 / day, about 10mg / m 2 / day and about 900mg / m 2 / day; for example, about 10 mg / m 2 / day, about 20mg / m 2 / day, about 30mg / m 2 / day, about 40mg / m 2 / day, about 40mg / m 2 / day, about 50mg / m 2 / day, about 60mg / m 2 / day, about 70mg / m 2 / day, about 80mg / m 2 / day, about 90mg / m 2 / day, about 100 mg / m 2 / day, about 500mg / m 2 / day or about 900 mg / m 2 A preferred dosing regimen involves treating a patient comprising administering to the patient about 300 mg / m daily prior to administering to the patient a therapeutically effective amount of engineered T cells. 2 / day of cyclophosphamide and about 30 mg / m 2 / day of fludarabine for three days.
[0297] In some embodiments, lymphocyte depletion further comprises administration of a CD52 antibody. In some embodiments, the CD52 antibody is alemtuzumab. In some embodiments, the CD52 antibody is administered IV at a dose of about 13 mg / day.
[0298] In other embodiments, the antigen binding domain, transduced (or otherwise engineered) cells, and chemotherapeutic agent are each administered in an amount effective to treat the disease or disorder in the subject.
[0299] In certain embodiments, the compositions comprising the CAR-expressing immune effector cells disclosed herein may be administered with any number of chemotherapeutic agents that may be administered in any order. Examples of chemotherapeutic agents include alkylating agents such as thiotepa and cyclophosphamide. TM); alkyl sulfonates, such as busulfan, improsulfan, and piposulfan; aziridines, such as benzodopa, carboquone, meturedopa, and uredopa; ethyleneimines and methylmelamines, including hexamethylmelamine, triethylenemelamine, triethylenephosphamide, triethylenethiophosphamide, and trishydroxymethylmelamine; nitrogen mustards, such as chlorambucil, naphthyl mustard, chlorphosphamide, estramustine, ifosfamide, dichloromethane, dichloromethane oxide hydrochloride, melphalan, novemb ichin), cholesterol, phenylacetic acid mustard, prednisone mustard, trolofosamide, uracil mustard; nitrosoureas, such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, ranimustine; antibiotics, such as aclarubicin, actinomycin, oslamectin, azaserine, bleomycin, actinomycin C, calicheamicin, carabicin, carminomycin, chromomycin, dactinomycin, daunomycin, detorubicin, 6-diazo-5-oxo-L-leuprocin ammonia, doxorubicin, epirubicin, esorubicin, idarucizumab, mexilomycin, mitomycin, mycophenolic acid, nogamycin, olivetomycin, peplomycin, sphaminomycin, puromycin, quinamycin, rodorubicin, streptozocin, streptozotocin, tuberculocidin, ubenimex, zinostatin, zorubicin; antimetabolites, such as methotrexate and 5-fluorouracil (5-FU); folic acid analogs, such as dinotin, methotrexate, pteropterin, trimetrexate; purine analogs, such as fludarabine, Labine, 6-mercaptopurine, thiabendazole, thioguanine; pyrimidine analogs, such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, 5-FU; androgens, such as captestosterone, drostanolone propionate, cyclothiodine, melastane, testolactone; antiadrenal agents, such as aminoglutethimide, mitotane, trilostane; folic acid supplements, such as folinic acid; acetoglucosalactone; aldophosphamide glycosides; aminolevulinic acid; amsacrine; bestabuc; bisantrene; idatrox; defuvalamide; colchicine; diazocone; efamixin; elinium acetate; etoglu; gallium nitrate; hydroxyurea; lentinan; lonidamine; mitoguanidine; mitoxantrone; mopidarol; niteracrine;pentostatin; phenamet; pirarubicin; podophyllic acid; 2-acetylhydrazine; procarbazine; Razoxane; sizoran; spirogermanium; tricosporin; triazoline; 2,2',2"-trichlorotriethylamine; urethane; vindesine; dacarbazine; mannochloridone; dibromomannitol; dibromodulanol; piperobroman; metoclotrine; arabinoside ("Ara-C"); cyclophosphamide; thiotepa; taxanes, such as paclitaxel (TAXOL TM , Bristol-Myers Squibb Oncology, Princeton, NJ) and doxetaxel ( Rhne-Poulenc Rorer, Antony, France; chlorambucil; gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisplatin and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitomycin C; mitoxantrone; vincristine; vinorelbine; navelbine; mitoxantrone; teniposide; daunomycin; aminopterin; xeloda; ibandronate; CPT-11; topoisomerase inhibitor RF S2000; difluoromethylornithine (DMFO); retinoic acid derivatives such as Targretin TM (Beselotin), Panretin TM (Yali Cuitonin);ONTAK TM (denileukin); esperamicin; capecitabine; and pharmaceutically acceptable salts, acids or derivatives of any of the above. This definition also includes anti-hormonal agents used to regulate or inhibit the effects of hormones on tumors, such as anti-estrogens, including, for example, tamoxifen, raloxifene, aromatase inhibition 4 (5) -imidazole, 4-hydroxytamoxifen, troxifene, raloxifene hydrochloride, LY117018, onapristone and toremifene (Fareston); and anti-androgens, such as flutamide, nilutamide, bicalutamide, leuprolide and goserelin; and pharmaceutically acceptable salts, acids or derivatives of any of the above. Combinations of chemotherapeutic agents are also administered when appropriate, including but not limited to CHOP, i.e. cyclophosphamide Doxorubicin (hydroxydoxorubicin), vincristine and prednisone.
[0300] In some embodiments, a chemotherapeutic agent is administered simultaneously or within a week after the engineered cell, polypeptide, or nucleic acid is administered. In other embodiments, a chemotherapeutic agent is administered 1 to 4 weeks, 1 week to 1 month, 1 week to 2 months, 1 week to 3 months, 1 week to 6 months, 1 week to 9 months, or 1 week to 12 months after the engineered cell, polypeptide, or nucleic acid is administered. In other embodiments, a chemotherapeutic agent is administered at least 1 month before the cell, polypeptide, or nucleic acid is administered. In some embodiments, the method further comprises administering two or more chemotherapeutic agents.
[0301] A variety of other therapeutic agents can be used in combination with the compositions described herein. For example, other therapeutic agents that may be useful include PD-1 inhibitors, such as nivolumab Pembrolizumab Pembrolizumab, pidilizumab, and atezolizumab
[0302] Other therapeutic agents suitable for combination with the present disclosure include, but are not limited to: ibrutinib Ofatumumab Rituximab Bevacizumab Trastuzumab Trastuzumab Enbrel Imatinib Cetuximab ( Panitumumab Catumaxomab, ibritumomab tiuxetan, ofatumumab, tositumomab, brentuximab, alemtuzumab, gemtuzumab, erlotinib, gefitinib, vandetanib, afatinib, lapatinib, neratinib, axitinib, masitinib, pazopanib, sunitinib, sorafenib, tocitanib, lestaurine, axitinib, cediranib, lenvatinib, nintedanib, pazopanib, regorafenib, semasanib, sorafenib, sunitinib, tivozanib, tocitanib, vandetanib, entrectinib, cabozantinib, imatinib Tinib, dasatinib, nilotinib, ponatinib, radotinib, bosutinib, lestautinib, ruxolitinib, paclitinib, cobimetinib, selumetinib, trametinib, binimetinib, alectinib, ceritinib, crizotinib, aflibercept, adipotide, denileukin-toxin conjugates, mTOR inhibitors (such as everolimus and temsirolimus), hedgehog inhibitors (such as sonidegi and vimodigib), CDK inhibitors (such as CDK inhibitor (palbociclib)).
[0303] In some embodiments, the composition including the immune cells containing CAR can be administered together with the treatment regimen to prevent cytokine release syndrome (CRS) or neurotoxicity. The treatment regimen for preventing cytokine release syndrome (CRS) or neurotoxicity can include lenzilumab, tocilizumab, atrial natriuretic peptide (ANP), anakinra, iNOS inhibitors (eg, L-NIL or 1400W). In additional embodiments, the composition including the immune cells containing CAR can be administered together with an anti-inflammatory agent. Anti-inflammatory agents or drugs include, but are not limited to, steroids and glucocorticoids (including betamethasone, budesonide, dexamethasone, hydrocortisone acetate, hydrocortisone, hydrocortisone, methylprednisolone, prednisolone, prednisone, triamcinolone); non-steroidal anti-inflammatory drugs (NSAIDS), including aspirin, ibuprofen, naproxen, methotrexate, sulfasalazine, leflunomide, anti-TNF agents, cyclophosphamide, and mycophenolate. Exemplary NSAIDs include ibuprofen, naproxen, naproxen sodium, Cox-2 inhibitors, and sialates. Exemplary analgesics include acetaminophen, oxycodone, tramadol with propoxyphene hydrochloride. Exemplary glucocorticoids include cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, or prednisone. Exemplary biological response modifiers include molecules directed to cell surface markers (e.g., CD4, CD5, etc.), cytokine inhibitors such as TNF antagonists (e.g., etanercept, ), Adalimumab and infliximab Chemokine inhibitors and adhesion molecule inhibitors. Biological response modifiers include monoclonal antibodies as well as recombinant forms of molecules. Exemplary DMARDs include azathioprine, cyclophosphamide, cyclosporine, methotrexate, penicillamine, leflunomide, sulfasalazine, hydroxychloroquine, gold (oral (auranofin) and intramuscular) and minocycline.
[0304] In certain embodiments, the compositions described herein are administered in combination with cytokines. Examples of cytokines are lymphokines, monokines, and traditional polypeptide hormones. Among the cytokines are growth hormones, such as human growth hormone, N-methionyl human growth hormone, and bovine growth hormone; parathyroid hormone; thyroxine; insulin; proinsulin; relaxin; prorelaxin; glycoprotein hormones, such as follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), and luteinizing hormone (LH); liver growth factor (HGF); fibroblast growth factor (FGF); prolactin; placental lactogen; mullerian inhibitory substance; mouse gonadotropin-related peptide; inhibin; activin; vascular endothelial growth factor; integrin; thrombopoietin (TPO); nerve growth factor (NGF), such as NGF-β; platelet growth factor; transforming growth factor (TGF), such as TGF-α and TGF-β; insulin-like growth factor-I and II; erythropoietin (EPO); osteoinductive factors; interferons, such as interferon-α, β and γ; colony stimulating factors (CSF), such as macrophage-CSF (M-CSF), granulocyte-macrophage-CSF (GM-CSF) and granulocyte-CSF (G-CSF); interleukins (Il), such as IL-1, IL-1α, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-15, IL-21; tumor necrosis factor, such as TNF-α or TNF-β; and other polypeptide factors, including LIF and kit ligand (KL). As used herein, the term cytokine includes proteins from natural sources or from recombinant cell culture, as well as biologically active equivalents of native sequence cytokines.
[0305] 7. Kits and Products
[0306] The present disclosure provides a kit including a reagent for analyzing a cell group as described herein, the cell group including a donor cell group and an engineered cell group, including a CAR T drug product. In some embodiments, the kit includes one or more reagents for detecting one or more biomarkers, the biomarkers including HLA-DR, TIGIT, CD16, CD56, CD27, CCR7 and CD45RA. The reagent can be an antigen binding molecule with specificity for one or more biomarkers, such as an antibody as described herein. In some embodiments, the kit also includes one or more reagents for detecting CAR. In some embodiments, the kit also includes one or more reagents for detecting TCRab. In some embodiments, the kit includes one or more reagents for analyzing a cell group as described herein according to the method described herein, wherein the one or more reagents are conjugated with a detection label. The kit may also include instructions for using a reagent to detect the level of one or more biomarkers, wherein the level detected indicates the expression percentage of one or more biomarkers described herein. In another embodiment, the kit may further include a reagent for measuring the in vitro function of engineered immune cells (eg, CAR T cells). The measured in vitro function may include in vitro cytotoxicity, mitochondrial fitness and / or cytokine secretion analysis.
[0307] The present disclosure also provides kits comprising any of the cultured immune cells or engineered immune cells described herein, and their pharmaceutical compositions. In some exemplary embodiments, the kits of the present disclosure include allogeneic CAR T cells for administration to a subject.
[0308] The present application also provides an article of manufacture comprising any of the therapeutic compositions or kits described herein. Examples of articles of manufacture include vials (eg, sealed vials).
[0309] The following examples are for illustrative purposes only. Indeed, various modifications of the invention in addition to those shown and described herein will be apparent to those skilled in the art from the foregoing description.
[0310] Example
[0311] Example 1 - Biomarker Characterization of Donor Cell Populations
[0312] Peripheral blood mononuclear cells (PBMCs) and CD4+CD8+ cells enriched from PBMCs were surface stained with markers of T cell phenotype, exhaustion, activation, and markers that distinguish different cell types. Data for stained cells were acquired using a BD LSR Fortessa X-20. Differences between donors can be characterized by flow cytometry, with young donors tending to have higher expression of young T cell phenotype markers (e.g., CC chemokine receptor 7 (CCR7), CD45RA, etc.) and lower expression of exhaustion markers (e.g., TIGIT). Other expression marker levels observed included human leukocyte antigen-DR isotype (HLA-DR), CD27, CD16, and CD56.
[0313] In addition, CAR-T cells derived from donor cells were stained similarly according to the process described in Example 2 to detect different markers at the end of the CAR-T preparation process. Table 1A provides the percentage range of cells expressing each biomarker in the tested CAR-T cell population. As described in Example 2, the in vitro toxicity of the CAR-T cell population was tested using a long-term killing assay (LTKA). Table 1A provides exemplary percentages of biomarker expression associated with improved in vitro cytotoxicity in CAR-T cells. For example, a CAR-T cell population with less than 65% of cells expressing HLA-DR exhibits stronger in vitro cytotoxicity than a CAR-T cell population with more than 65% of cells expressing HLA-DR.
[0314] Table 1A
[0315]
[0316]
[0317] Example 2 - In vitro functional analysis of CAR T cells derived from donor cell populations
[0318] The donor cell population described in Example 1 was used to engineer CAR T cells targeting B cell maturation antigen (BCMA) (e.g., as described in Kuo et al. U.S. Pat. No. 10,294,304, such as Example 2, which is incorporated herein by reference in its entirety). Briefly, CAR T cells were prepared from healthy donor PBMCs in a process involving lentiviral transduction containing a CAR scFv transgene that recognizes BCMA. TransAct TM Activator (MACS GMP T cell TransAct TM) to inoculate and activate cells to induce T cell activation and proliferation. The cells were then plated in six-well plates, where the LVV contained a construct expressing BCMA scFv / 4-1BB / CD3ζCAR. Then, Lonza TM The 4D Nuclear Transfection System electroporates mRNA was transfected into T cells to genetically disrupt TRAC and CD52 genes and TCRαβ and CD52 protein expression. At the end of preparation, CAR T cells were cultured in CS5 solution and stored in a liquid nitrogen freezer for further functional characterization.
[0319] CAR T cells were then analyzed using various in vitro functional assays, including cytotoxicity, mitochondrial fitness, and cytokine secretion assays.
[0320] Cytotoxicity. CAR T cell cytotoxicity was determined using a short-term killing assay (STKA) and a long-term killing assay (LTKA).
[0321] STKA.Frozen CAR T cells and untransduced cells were thawed and checked for viability and cell counts with Beckman Coulter's Vi-Cell XR analyzer. CAR+% of different donors was normalized with untransduced cells so that all donors had the same CAR+% and total number of T cells. The assay was set up in a 96-well flat-bottom plate, with the same number of MM1s-GFP-Luc cells as target cells, and the number of T cells was changed to achieve an effector cell (CAR T cell) to target cell ratio of 10: 1, 5: 1, 2.5: 1, 1.25: 1, 0.625: 1, 0.3: 1 and 0.15: 1. For each condition, triplicate wells were prepared, and the plates were stored in an incubator at 37°C, supplemented with CO2 after setting. After overnight incubation (about 24 hours), cytotoxicity was measured by measuring luciferase signals using the Promega Bright-Glo luciferase assay system on the Promega GloMax instrument.
[0322] LTKA. Frozen CAR T cells and untransduced cells were thawed and checked for viability and cell counts using Beckman Coulter's Vi-Cell XR analyzer. The CAR+% of different donors was normalized with untransduced cells so that all donors had the same CAR+% and total number of T cells. The assay was set up in a 96-well flat-bottom plate with the same number of MM1s-GFP-Luc cells as target cells and the number of T cells was varied to achieve a 2:1, 1:1, or 1:2 ratio of effector cells (CAR T cells) to target cells. For each condition, quadruplicate wells were prepared and the plates were kept in a 37°C, CO2-supplemented incubator after setup. Every 2–3 days, half of the cells were transferred to a new 96-well flat-bottom plate and re-stimulated with the same amount of target cells as set up to evaluate long-term cytotoxicity and persistence, while the other half of the cells were used to measure cytotoxicity, but the luciferase signal was measured using the Promega Bright-Glo Luciferase Assay System on the Promega GloMax instrument. The assay was continued until no cytotoxicity was observed.
[0323] Figure 1A-1B Correlations between in vitro CAR T cell function (long-term killing assay or LTKA) and certain biomarkers on CD8+ CAR-T cells at the end of CAR-T cell preparation are depicted. Figure 1A Depicted are the positive correlations observed between in vitro CAR-T function and the expression of (i) CD27, CCR7, and CD45RA (upper left panel) or (ii) CD27 and CD45RA (upper right panel). Figure 1A Also depicted are (i) the observed negative correlation between in vitro CAR-T function and the expression of (i) T cell immunoreceptor with Ig and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT) (lower left panel) or (ii) human leukocyte antigen-DR isotype (HLA-DR) (lower right panel) on T cells at the end of CAR T cell preparation. Figure 1B The observed negative correlation between in vitro CAR T function and the expression of CD56 or CD16 on CD8+ CAR-T cells at the end of CAR T cell preparation is depicted. The expression of early T cell phenotypic markers and exhaustion markers was found to trend with in vitro anti-tumor activity. Additional donors were evaluated for LTKA correlation and the following observations were made: i) Positive correlation between LTKA and the percentage of the CD27, CCR7 and CD45RA triple positive population - R 2 =0.219, p=0.009 and N=30; ii) Positive correlation between LTKA and the percentage of CD27 and CD45RA double positive population - R 2=0.15, p=0.034 and N=30; iii) Negative correlation between the expression of LTKA and TIGIT - R 2 =0.218, p=0.009 and N=30; iv) Negative correlation between LTKA and HLA-DR expression - R 2 =0.28, p=0.003 and N=30; v) Negative correlation between LTKA and CD56 expression - R 2 =0.178, p=0.05 and N=28; and vi) negative correlation between LTKA and CD16 expression - R 2 =0.353, p=0.0036 and N=28.
[0324] Mitochondrial fitness. The mitochondrial fitness of CAR T cells was characterized using the Agilent Seahorse XF Cell Mitochondrial Stress Test Kit. Frozen CAR T cells were thawed and viability and cell counts were checked using the Beckman Coulter Vi-Cell XR Analyzer. The cell concentration was adjusted to 1 x 10 in R10 medium (RPMI + 10% HI-FBS + 1x non-essential amino acids + 1x sodium pyruvate). 6 cells / ml and allowed to rest in a 37°C, CO2-supplemented incubator for at least 1 hour. Following incubation, the assay was performed according to the manufacturer's protocol and data were collected using a Seahorse XFe96 analyzer. The instrument measures the spare respiratory capacity (SRC), which indicates how much extra energy the cell can provide in an emergency, and a higher SRC indicates that the cell has more suitable mitochondrial function. A positive trend was observed between the SRC values and the cytotoxicity results of LTKA ( Figure 1C ), and young healthy donors also had slightly higher SRC compared with old donors, suggesting a potential relationship between mitochondrial fitness and donor characteristics.
[0325] Cytokine Secretion Analysis. Cytokine secretion was measured at the single cell level to generate a polyfunctional strength index (PSI) for donor cell starting material or thawed CAR T cells (Isoplexis Isocode technology). Briefly, CD4 / CD8 enriched cells from PBMC (CD3+) were stimulated with SEB or TransAct. On day zero, CD4 / CD8 enriched cells were isolated from PBMC, stimulants were added and incubated overnight. On day 1, the cells were then stained with stain A and loaded onto the chip. Data was collected on IsoLight. Using the formula below, PSI measures cytokine secretion capacity at the single cell level, and intrinsic differences in cytokine secretion between donors are observed through this assay.
[0326]
[0327] In another experiment, thawed CAR T cells were separated based on CD4 / 8 expression (CD4+ or CD8+) and stimulated with target cells (MM1s). On day zero, CAR T cells were thawed and recovered overnight in IL-2 at a concentration of 1M / ml. On day 1, CD4+ and CD8+ cells were separated and incubated with target cells overnight at an E:T ratio of 1:2. On day 2, T cells were separated from target cells, stained with CD4- or CD8-AF647 and loaded onto the chip. Data were collected on IsoLight. Similar to the above results, different donors had various cytokine secretion capabilities. However, single cell cytokine secretion potency showed a negative trend with T cell cytotoxicity. ( Figure 1D ). Without being bound by theory, one explanation for these results is that cells may have limited energy under stress conditions and there is competition between cytokine production and cytotoxicity, thus leading to a negative trend between the two assays. An interesting observation is that the PSI of both CAR T cells and starting materials from young healthy donors tends to be lower compared to healthy donors aged>30 years. Although the difference is not significant, this can be an attribute for further analysis to help deepen the understanding of donor differences. In summary, different donor cell populations are used to generate CAR T cell populations, and then certain biomarkers and functional attributes of these CAR T cell populations are analyzed. Table 1B summarizes the results of using cells from different types of donor populations: i) healthy ideal and ii) cancer patients.
[0328] In addition to the median (50%), Q1 (25%) and Q3 (75%) values for the range of the data between the minimum and maximum values are provided. These Q1 and Q3 values provide additional insights when comparing healthy ideal donors to cancer patients. For example, the differences in the median and range (maximum minus minimum) of STKA AUC between healthy ideal donors and cancer patients are not obvious; however, the Q1 and Q3 values of healthy ideal donors are consistently higher than those of cancer patients. The additional Q1 and Q3 values provide information about the distribution of the data and indicate the overall superior cytotoxicity of healthy ideal donors. In the case of the PSI of CD8+CAR T cells, which showed a negative correlation with LTKA efficacy, although the minimum value was lower in cancer patients, the added Q1 information showed a trend of higher PSI values in cancer patients and provided deeper insights into the data distribution.
[0329] Table 1B
[0330]
[0331]
[0332] Example 3 - Allogeneic CAR T cells derived from young donor T cells have a more desirable T cell phenotype and better in vitro function
[0333] Autologous chimeric antigen receptor (CAR) T cell therapy has shown promising efficacy in the treatment of relapsed / refractory B-cell malignancies. Despite clinical success, autologous CAR T cell therapy has disadvantages, including delays in treating patients and the inability to treat all patients due to manufacturing failures caused by functionally defective T cells present in this patient population. In contrast, the allogeneic CAR T cell therapy under investigation uses T cells from healthy individuals as starting material, simplifying supply and providing the convenience of a ready-made product. The use of healthy donor T cells also opens up the possibility of optimizing therapeutic efficacy and providing a more homogeneous product by using immunologically suitable donor T cells. Given that most CAR T cell performance evaluations are performed with patient-derived CAR T cells, it is unclear what constitutes an unsuitable donor for allogeneic T cell therapy.
[0334] To understand factors that influence donor suitability, the study evaluated T cells from 19 healthy donors. The selected healthy donors varied in age (range: 18–62) and body mass index (BMI) (range: 19-52) to capture a wide range of physical health conditions and evaluate the effects of age and BMI on CAR T cell phenotype and function. In addition, T cells from 11 donors with relapsed / refractory heme malignancies (referred to here as patient-derived T cells) were also included in the donor pool as a control of functionally deficient T cells, simulating autologous CAR T cell therapy.
[0335] T cells were isolated from the peripheral blood mononuclear cells (PBMC) of these 30 donors and used as starting materials to generate CART cells. During the production of CAR T cells in the laboratory, due to the limited number of live suitable T cells in the starting material, 6 of the 11 patient-derived T cell preparations could not be expanded. However, CAR T cells (19 healthy donors and 5 patient-derived T cell preparations) were successfully generated from the remaining 24 donors.
[0336] These CAR T cell batches were further characterized using a battery of in vitro assays, including deep immunophenotyping by flow cytometry and cytotoxicity assays. Correlation analysis revealed an inverse correlation between in vitro antitumor activity and increasing donor age.
[0337] Furthermore, there is an inverse correlation between the percentage of less differentiated T cells in the starting material and in the CAR T-cell product and age, with older donors having fewer stem / central memory T cells than younger donors. Figure 2A As shown in (CD8 T cell phenotype - starting material) and Figure 2B (CD8 T cell phenotype after CAR T preparation). Asterisks (*) indicate non-ideal donors with BMI>30. Diseased donors (providing patient-derived T cells) are labeled with disease (ALL: acute lymphoblastic leukemia; MM: multiple myeloma; CLL: chronic lymphocytic leukemia; and NHL: non-Hodgkin's lymphoma).
[0338] Although the percentage of stem cell memory T cells (TSCM) in the starting material was similar to that of age-matched healthy donors, the percentage of TSCM in patient-derived CAR T cells at the end of culture tended to be lower compared to CAR T cells generated from healthy donor material, highlighting the limited fitness of disease donor T cells ( Figure 3A - Starting materials and Figure 3B – after CAR T preparation). It was found that both donor age and disease status were associated with lower Tscm%, and this difference increased during CAR T preparation. Both donor age and disease status resulted in lower Tscm% in the starting material. In addition, disease status was also associated with lower Tscm% at the end of CAR T preparation.
[0339] Figure 4A-4B T cells from young donors were shown to have a younger T cell phenotype, lower expression of exhaustion markers (e.g., HLA-DR and TIGIT), and better in vitro cytotoxicity.
[0340] Statistically significant correlations between expression of specific T cell activation markers and inhibitory markers and poor in vitro anti-tumor activity were also observed (data not shown). The expression of these specific T cell markers was positively correlated with increasing age. The findings of this study demonstrate the opportunity to use young healthy donor material for allogeneic CAR T products, potentially eliminating manufacturing failures and improving patient outcomes.
Claims
1. A method for preparing engineered immune cells, the method comprising: a) detecting that the HLA-DR expression level in the immune cell population is 65% or less; as well as b) modifying the immune cell population to express an exogenous nucleic acid sequence, thereby providing an engineered immune cell population.
2. The method of claim 1, wherein the exogenous nucleic acid sequence comprises a chimeric antigen receptor (CAR) nucleic acid sequence.
3. The method of claim 2, wherein the exogenous nucleic acid sequence further comprises one or more nucleic acid sequences selected from the group consisting of: a chimeric antigen receptor (CAR), a transmembrane domain nucleic acid sequence, a co-stimulatory domain nucleic acid sequence, and a signaling domain nucleic acid sequence.
4. The method of claim 3, wherein the exogenous nucleic acid sequence is expressed as a single transcript.
5. The method of claim 1, wherein the engineered immune cell population has improved in vitro function compared to a non-engineered immune cell population.
6. The method of claim 1, wherein the engineered immune cell population has improved in vitro function compared to an additional engineered immune cell population derived from an additional immune cell population that expresses HLA-DR at a level greater than about 65%.
7. The method of claim 5 or 6, wherein the improved in vitro function comprises one or more of improved in vitro cytotoxicity, improved cell fitness, and reduced cytokine secretion.
8. The method of claim 7, wherein the cytotoxicity is demonstrated by an in vitro killing assay.
9. The method of claim 8, wherein the cytotoxicity is demonstrated by an in vitro killing assay comprising killing cells expressing the target of the CAR.
10. The method of claim 8 or 9, wherein the in vitro killing assay is a long-term killing assay or a short-term killing assay.
11. The method of claim 8 or 9, wherein the in vitro killing assay is a long-term killing assay or a short-term killing assay.
12. The method of claim 2 or 3, wherein the CAR nucleic acid sequence expresses a CAR that binds to BCMA, EGFRvIII, WT-1, CD20, CD23, CD30, CD38, CD33, CD133, MHC-WT1, TSPAN10, MHC-PRAME, Liv1, ADAM10, CHRNA2, LeY, NKGD2D, CS1, CD44v6, ROR1, Claudin-18.2, Muc17, FAP alpha, Ly6G6D, c6orf23, G6D, MEGT1, NG25, CD19, FLT3, CD70, DLL3, CD52 or CD34.
13. The method of claim 1, wherein the modification further comprises reducing or eliminating the expression or activity of an endogenous gene.
14. The method of claim 1, wherein prior to the detecting step, the immune cell population is obtained or derived from a donor.
15. The method of claim 14, wherein the donor is a healthy donor or a patient in need of treatment.
16. The method of claim 15, wherein the patient is a patient in need of treatment with autologous cell therapy.
17. The method of claim 16, wherein the autologous cell therapy comprises the engineered immune cell population.
18. The method of claim 1, wherein detecting comprises detecting the protein level of HLA-DR using flow cytometry (FACS), enzyme-linked immunosorbent assay (ELISA), immunoblotting assay, immunofluorescence assay, or immunochemistry (IHC) assay.
19. The method of any one of claims 1 to 15 and 18, wherein the immune cell population is obtained from a healthy human donor.
20. The method of claim 19, wherein the healthy human donor is between about 18 and about 30 years old.
21. The method of any one of claims 1-20, further comprising detecting the expression level of one or more biomarkers selected from the group consisting of: TIGIT, CD16, CD56, CCR7, CD27, and CD45RA.
22. The method of any one of claims 1-20, further comprising detecting the expression level of TIGIT.
23. The method of claim 22, wherein the expression level of TIGIT in the immune cell population is 30% or less.
24. The method of any one of claims 1-23, further comprising depleting HLA-DR positive immune cells from the immune cell population to provide an HLA-DR depleted immune cell population.
25. The method of any one of claims 1-24, further comprising deleting TIGIT-positive immune cells from the immune cell population to provide a TIGIT-deleted immune cell population.
26. A method as claimed in claim 24 or 25, wherein the trimming step is preceded by a removal step.
27. An engineered immune cell population comprising 65% or less HLA-DR+ cells.
28. The engineered immune cell population of claim 27, comprising 30% or less TIGIT+ cells.
29. The engineered immune cell population of claim 27 or 28, comprising an exogenous nucleic acid sequence.
30. The engineered immune cell population of claim 29, comprising an exogenous nucleic acid sequence comprising a chimeric antigen receptor (CAR) nucleic acid sequence.
31. The engineered immune cell population of claim 29, wherein the exogenous nucleic acid sequence comprises one or more nucleic acid sequences selected from the group consisting of: a CAR, a transmembrane domain nucleic acid sequence, a co-stimulatory domain nucleic acid sequence, and a signaling domain nucleic acid sequence.
32. The engineered immune cell population of any one of claims 29-31, wherein the exogenous nucleic acid sequence is expressed as a single transcript.
33. A method for preparing immune cells with improved in vitro function, the method comprising: a) detecting the HLA-DR expression level in the immune cell population to provide a detected HLA-DR expression level; as well as b) modifying the immune cell population to express an exogenous nucleic acid sequence, thereby providing an engineered immune cell population, wherein the engineered immune cell population comprises or exhibits improved in vitro function compared to an additional engineered immune cell population derived from an additional immune cell population having an additional HLA-DR expression level above said detectable level.
34. A method as claimed in claim 33, wherein the detected level indicates that HLA-DR is expressed in less than 65% of the immune cells of the immune cell population, and optionally wherein (a) the additional HLA-DR level is expressed in greater than 65% of the immune cells of the additional immune cell population, and / or (b) detecting further includes detecting the TIGIT expression level in the immune cell population, wherein the TIGIT expression level detected in the immune cell population is 30% or less.
35. The method of claim 33, wherein the exogenous nucleic acid sequence comprises a chimeric antigen receptor (CAR) nucleic acid sequence.
36. The method of claim 35, wherein the exogenous nucleic acid sequence further comprises one or more nucleic acid sequences selected from the group consisting of a chimeric antigen receptor (CAR), a transmembrane domain nucleic acid sequence, a co-stimulatory domain nucleic acid sequence, and a signaling domain nucleic acid sequence.
37. The method of claim 36, wherein the exogenous nucleic acid sequence is expressed as a single transcript.
38. The method of claim 33, wherein the improved in vitro function comprises or exhibits one or more of improved in vitro cytotoxicity, improved cell fitness, and reduced cytokine secretion.
39. The method of claim 35 or 36, wherein the improved in vitro function comprises or exhibits one or more of improved in vitro cytotoxicity, improved cell fitness, and reduced cytokine secretion.
40. The method of claim 38 or 39, wherein the cytotoxicity is demonstrated by an in vitro killing assay.
41. The method of claim 39, wherein the cytotoxicity is demonstrated by an in vitro killing assay comprising killing cells expressing the target of the CAR.
42. The method of claim 40, wherein the in vitro killing assay is a long-term killing assay or a short-term killing assay.
43. The method of claim 41, wherein the in vitro killing assay is a long-term killing assay or a short-term killing assay.
44. The method of claim 33, wherein the detected level indicates that HLA-DR is expressed in less than 65% of the immune cells of the immune cell population, and wherein the additional level of HLA-DR is expressed in greater than 65% of the immune cells of the additional immune cell population.
45. The method of claim 35, wherein the CAR nucleic acid sequence expresses a CAR that binds to BCMA, EGFRvIII, WT-1, CD20, CD23, CD30, CD38, CD33, CD133, MHC-WT1, TSPAN10, MHC-PRAME, Liv1, ADAM10, CHRNA2, LeY, NKGD2D, CS1, CD44v6, ROR1, Claudin-18.2, Muc17, FAP alpha, Ly6G6D, c6orf23, G6D, MEGT1, NG25, CD19, FLT3, CD70, DLL3, CD52 or CD34.
46. The method of claim 33, wherein the modification further comprises reducing or eliminating the expression or activity of an endogenous gene.
47. The method of claim 33, wherein prior to the detecting step, the immune cell population is obtained or derived from a donor.
48. The method of claim 47, wherein the donor is a healthy donor or a patient in need of treatment.
49. The method of claim 48, wherein the patient is a patient in need of treatment with autologous cell therapy.
50. The method of claim 49, wherein the autologous cell therapy comprises the engineered immune cell population.
51. The method of claim 33, wherein detecting comprises detecting the protein level of HLA-DR using flow cytometry (FACS), enzyme-linked immunosorbent assay (ELISA), immunoblotting assay, immunofluorescence assay, or immunochemistry (IHC) assay.
52. A method for selecting a donor immune cell population for engineering, the method comprising: a) detecting a first HLA-DR expression level in a first immune cell population to provide a first detected HLA-DR level; b) detecting a second HLA-DR expression level in a second population of immune cells to provide a second detected HLA-DR level, wherein the second detected level is greater than the first detected level; as well as c) selecting said first immune cell population for engineering.
53. The method of claim 52, wherein the first detected level indicates that HLA-DR is expressed in less than 65% of the immune cells in the population of immune cells.
54. The method of claim 53, wherein the second detected level indicates that HLA-DR is expressed in greater than 65% of the immune cells in the population of immune cells.
55. The method of claim 52, further comprising modifying the first immune cell population to express an exogenous nucleic acid sequence, thereby providing an engineered immune cell population.
56. The method of claim 55, wherein the engineered immune cell population comprises or exhibits improved in vitro function compared to another engineered immune cell population derived from the second immune cell population.
57. The method of claim 55, wherein the exogenous nucleic acid sequence comprises a chimeric antigen receptor (CAR) nucleic acid sequence.
58. The method of claim 57, wherein the exogenous nucleic acid sequence further comprises one or more nucleic acid sequences selected from the group consisting of: a CAR, a transmembrane domain nucleic acid sequence, a co-stimulatory domain nucleic acid sequence, and a signaling domain nucleic acid sequence.
59. The method of claim 58, wherein the exogenous nucleic acid sequence is expressed as a single transcript.
60. The method of claim 56, wherein the improved in vitro function comprises one or more of improved in vitro cytotoxicity, improved cell fitness, and reduced cytokine secretion.
61. The method of claim 60, wherein the cytotoxicity is demonstrated by an in vitro killing assay.
62. The method of claim 60, wherein the cytotoxicity is demonstrated by an in vitro killing assay comprising killing cells expressing the target of the CAR.
63. The method of claim 61, wherein the in vitro killing assay is a long-term killing assay or a short-term killing assay.
64. The method of claim 62, wherein the in vitro killing assay is a long-term killing assay or a short-term killing assay.
65. The method of claim 52, further comprising discarding the second cell population and / or retaining the first cell population.
66. The method of claim 52, wherein prior to the detecting step, the first immune cell population and / or the second immune cell population is obtained or derived from a donor.
67. The method of claim 66, wherein the donor is a healthy donor or a patient in need of treatment.
68. The method of claim 67, wherein the patient is a patient in need of treatment with autologous cell therapy.
69. The method of claim 68, wherein the autologous cell therapy comprises the engineered immune cell population.
70. The method of claim 52, wherein detecting comprises detecting the protein level of HLA-DR using flow cytometry (FACS), enzyme-linked immunosorbent assay (ELISA), immunoblotting assay, immunofluorescence assay, or immunochemistry (IHC) assay.
71. A method as claimed in claim 52, wherein the detection step (a) further includes detecting a first TIGIT expression level in the first immune cell population to provide a first detected TIGIT level, and the detection step (b) further includes detecting a second TIGIT expression level in the second immune cell population to provide a second detected TIGIT level, wherein the second detected TIGIT level is greater than the first detected TIGIT level.
72. The method of claim 71, wherein the first detected TIGIT level indicates that TIGIT is expressed in less than 30% of the immune cells in the immune cell population.
73. The method of claim 72, wherein the second detected TIGIT level indicates that TIGIT is expressed in greater than 30% of the immune cells in the immune cell population.
74. A method for preparing an immune cell having improved in vitro function, the method comprising: a) modifying an immune cell population to express an exogenous nucleic acid sequence, thereby providing an engineered immune cell population; as well as b) removing HLA-DR positive engineered immune cells from the engineered immune cell population to provide an HLA-DR removed engineered immune cell population, Wherein the HLA-DR-depleted engineered immune cell population comprises or exhibits improved in vitro function compared to an engineered immune cell population that is not depleted of HLA-DR-positive engineered immune cells.
75. The method of claim 74, further comprising removing additional immune cells from the engineered immune cell population, wherein the additional immune cells express one or more of TIGIT, CD16, and CD56.
76. The method of claim 74, wherein the exogenous nucleic acid sequence comprises a chimeric antigen receptor (CAR) nucleic acid sequence.
77. The method of claim 76, wherein the exogenous nucleic acid sequence further comprises one or more nucleic acid sequences selected from the group consisting of: a CAR, a transmembrane domain nucleic acid sequence, a co-stimulatory domain nucleic acid sequence, and a signaling domain nucleic acid sequence.
78. The method of claim 77, wherein the exogenous nucleic acid sequence is expressed as a single transcript.
79. The method of claim 74, wherein the improved in vitro function comprises one or more of improved in vitro cytotoxicity, improved cell fitness, and reduced cytokine secretion.
80. The method of claim 76 or 77, wherein the improved in vitro function comprises one or more of improved in vitro cytotoxicity, improved cell fitness, and reduced cytokine secretion.
81. The method of claim 79 or 80, wherein the cytotoxicity is demonstrated by an in vitro killing assay.
82. The method of claim 80, wherein the cytotoxicity is demonstrated by an in vitro killing assay comprising killing cells expressing the target of the CAR.
83. The method of claim 81, wherein the in vitro killing assay is a long-term killing assay or a short-term killing assay.
84. The method of claim 82, wherein the in vitro killing assay is a long-term killing assay or a short-term killing assay.
85. The method of claim 75, wherein the engineered immune cell population with HLA-DR deletion and TIGIT, CD16 or CD56 deletion comprises or exhibits improved in vitro function compared to an engineered immune cell population in which HLA-DR-positive and TIGIT, CD16 or CD56-positive immune cells are not deleted.
86. A method as described in claim 76, wherein the CAR nucleic acid sequence expresses a CAR that binds to BCMA, EGFRvIII, WT-1, CD20, CD23, CD30, CD38, CD33, CD133, MHC-WT1, TSPAN10, MHC-PRAME, Liv1, ADAM10, CHRNA2, LeY, NKGD2D, CS1, CD44v6, ROR1, Claudin-18.2, Muc17, FAP alpha, Ly6G6D, c6orf23, G6D, MEGT1, NG25, CD19, FLT3, CD70, DLL3, CD52 or CD34.
87. The method of claim 74, wherein the modification further comprises reducing or eliminating the expression or activity of an endogenous gene.
88. The method of claim 74, wherein prior to the modifying step, the immune cell population is obtained or derived from a donor.
89. The method of claim 88, wherein the donor is a healthy donor or a patient in need of treatment.
90. The method of claim 89, wherein the patient is a patient in need of treatment with autologous cell therapy.
91. The method of claim 90, wherein the autologous cell therapy comprises the engineered immune cell population.
92. The method of claim 74, wherein deleting comprises a flow cytometry (FACS) method.
93. The method of claim 74, further comprising detecting the level of HLA-DR expression in the HLA-DR knocked-out engineered immune cell population.
94. The method of claim 75, further comprising detecting the expression level of TIGIT in a population of engineered immune cells in which TIGIT has been knocked out.
95. A population of chimeric antigen receptor T (CAR-T) cells, wherein HLA-DR is expressed at a first level and the CAR-T cell population has improved in vitro function compared to a CAR-T cell population expressing HLA-DR at a second level, wherein the first level is lower than the second level.
96. The CAR-T cell population of claim 95, wherein the first level in the CAR-T cell population is 65% or less and / or wherein the second level in the CAR-T cell population is greater than 65%.
97. A CAR-T cell population as described in claim 95, wherein TIGIT is expressed at a first level and has improved in vitro function compared to a CAR-T cell population expressing TIGIT at a second level, wherein the first TIGIT expression level is lower than the second TIGIT expression level.
98. A CAR-T cell population as described in claim 97, wherein the first TIGIT expression level in the CAR-T cell population is 30% or less and / or wherein the second TIGIT expression level in the CAR-T cell population is greater than 30%.
99. The CAR-T cell population of claim 95, having an exogenous nucleic acid sequence comprising a chimeric antigen receptor (CAR) nucleic acid sequence.
100. The CAR-T cell population of claim 99, wherein the exogenous nucleic acid sequence further comprises one or more nucleic acid sequences selected from the group consisting of: CAR, a transmembrane domain nucleic acid sequence, a co-stimulatory domain nucleic acid sequence, and a signaling domain nucleic acid sequence.
101. The CAR-T cell population of claim 100, wherein the exogenous nucleic acid sequence is expressed as a single transcript.
102. The CAR-T cell population of any one of claims 95-100, wherein the improved in vitro function comprises one or more of improved in vitro cytotoxicity, improved cell fitness, and reduced cytokine secretion.
103. The CAR-T cell population of claim 102, wherein the cytotoxicity is demonstrated by an in vitro killing assay.
104. The CAR-T cell population of claim 102, wherein the cytotoxicity is demonstrated by an in vitro killing assay comprising killing cells expressing the target of the CAR.
105. The CAR-T cell population of claim 103 or 104, wherein the in vitro killing assay is a long-term killing assay or a short-term killing assay.
106. A CAR-T cell population as described in claim 99, wherein the CAR nucleic acid sequence expresses a CAR that binds to BCMA, EGFRvIII, WT-1, CD20, CD23, CD30, CD38, CD33, CD133, MHC-WT1, TSPAN10, MHC-PRAME, Liv1, ADAM10, CHRNA2, LeY, NKGD2D, CS1, CD44v6, ROR1, Claudin-18.2, Muc17, FAP alpha, Ly6G6D, c6orf23, G6D, MEGT1, NG25, CD19, FLT3, CD70, DLL3, CD52 or CD34.
107. A kit for in vitro functional analysis of a cell population, the kit comprising: a) anti-HLA-DR binding agents; as well as b) instructions for using the binding agent to detect the expression level of HLA-DR in a cell population.
108. The kit of claim 107, further comprising one or more additional binding agents to detect one or more of TIGIT, CD16, and CD56.
109. The kit of claim 107, further comprising a reagent for measuring the in vitro cytotoxicity of CART cells engineered from the cell population.
110. The kit of claim 107, wherein the binding agent is an antigen binding molecule.
111. The kit of claim 108, wherein the one or more additional binding agents are antigen binding molecules.
112. The kit of claim 109, wherein the antigen binding molecule is an antibody or a fragment thereof.
113. The kit of claim 111, wherein the one or more antigen binding molecules are one or more antibodies or fragments thereof.
114. The method of any one of claims 33-51, further comprising detecting the expression level of one or more biomarkers selected from the group consisting of: TIGIT, CD16, CD56, CCR7, CD27, and CD45RA.
115. The method of any one of claims 52-70, further comprising detecting a first expression level of one or more additional biomarkers selected from the group consisting of: TIGIT, CD16, CD56, CCR7, CD27, and CD45RA.
116. The method of any one of claims 52-70 and 115, further comprising detecting a second expression level of one or more additional biomarkers selected from the group consisting of: TIGIT, CD16, CD56, CCR7, CD27, and CD45RA.
117. The method of any one of claims 74-93, further comprising removing biomarker-positive engineered immune cells from the engineered immune cell population to provide a biomarker-removed engineered immune cell population, wherein the biomarker is selected from the group consisting of TIGIT, CD16 and CD56.
118. A CAR-T cell population as described in any one of claims 95-96 and 99-106, wherein a first biomarker is expressed at a third level and has improved in vitro function compared to a CAR-T cell population expressing the biomarker at a fourth level, wherein the third is lower than the fourth level, wherein the first biomarker is selected from the group consisting of TIGIT, CD16 and CD56.
119. A CAR-T cell population as described in any one of claims 95-96, 99-106 and 118, wherein a second biomarker is expressed at a fifth level and the CAR-T cell population has improved in vitro function compared to a CAR-T cell population expressing the biomarker at a sixth second level, wherein the fifth level is higher than the sixth level, and wherein the biomarker is selected from the group consisting of CCR7, CD27 and CD45RA.
120. The method of any one of claims 33-51 and 114, wherein the immune cell population is obtained from a healthy human donor.
121. The method of any one of claims 52-73 and 115-116, wherein the first population of immune cells is obtained from a healthy human donor.
122. The method of any one of claims 74-94 and 117, wherein the immune cell population is obtained from a healthy human donor.
123. The method of any one of claims 120-122, wherein the healthy human donor is between about 18 and about 30 years old.
124. A CAR-T cell population as described in any one of claims 95-106 and 118-119, wherein the CAR-T cell population is derived from a donor cell population obtained from a healthy human donor.
125. The method of claim 124, wherein the healthy human donor is between about 18 and about 30 years old.
